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RIN Rat insulinoma cell line
HIT Syrian hamster induced cell line
HIT-T15 T-1 5 Subclone of the Syrian hamster induced
cell line
HITm2.2 2.2 subclone of the Syrian hamster induced
tumour cell line from mouse tissue 
MIN Mouse insulinoma cell line
MIN-6 Mouse insulinoma induced tumour cell line 6
MIN-7 Mouse insulinoma induced tumour cell line 7
Glut 1 Erythrocyte transporter
Glut 2 Liver or pancreatic transporter
Glut 3 Fetal muscle and brain transporter
Glut 4 Skeletal muscle and adipocyte transporter
Glut 5 intestinal cell transporter
RINr Rat insulinoma cells from rat tissue
RINm Rat insulinoma cells from mouse tissue
RINm5f 5f subclone of rat insulinoma cells
Km Michaelis Menten kinetic constant
DNA Deoxyribose nucleic acid
cDNA Complementary deoxyribose nucleic acid
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THF Tetrahydrofuran
Summary
A characterization of the D-glucose transport systems in 
islet beta cell lines has been carried out. The cell 
lines used were HITm2.2, HIT-T15, RINm5f and MIN-6 and 
each of these lines were found to have different 
transport affinities and capacities to transport 
6-deoxy-D-glucose and D-fructose. The ability to 
transport D-fructose was considered to be an important 
criteria of whether the cell line represented a model of 
the hexose transport properties of intact islets which 
are known to possess the glucose transporter isoform 
glut 2, which can transport D-fructose. All the cell 
lines rapidly transported 6-deoxy-D-glucose. Tracer 
concentrations (100 pM) were equilibrated with half times 
of under 30 seconds. The Km and Vmax for 
6-deoxy-D-glucose were compared in each of the cell
lines. The Km and Vmax values indicated the presence of a
high affinity, high capacity transporter in the HIT and 
MIN-6 cell lines. Only the RINm5f cell line rapidly
transported D-fructose and it is proposed that this cell
line contains a separate transporter for D-fructose. From 
these studies it is inferred that the HITm2.2 and MIN-6 
cell lines probably express the glut 2 isoform and that 
the RIN and HIT-T15 cell lines possess a mixture of 
transporter isoforms.
7The sugar transport specificity requirements were 
investigated in the HITm2.2 and RINm5f cell lines.
Several differences in specificity were noted which were 
interpreted in terms of interaction of the sugar 
analogues with glut 2 rather than the more common 
erythrocyte isoform, glut 1 .
A radiolabelled analogue of the diabetogenic drug 
streptozotocin was synthesized. This compound is known to 
be cytotoxic for pancreatic islet beta cells and the 
hypothesis that this selective toxicity may be related to 
a selective uptake of the drug by the beta cells was 
explored using the beta cell lines HIT-T15 and MIN-6. In 
MIN-6 cells, the transport of streptozotocin was 
selectively inhibited by 6-deoxy-D-glucose and by 
D-fructose. 6-deoxy-D-glucose but not D-fructose 
inhibited transport into the HIT-T15 cell line. It is 
suggested that since the MIN-6 cells probably express 
glut 2, the streptozotocin uptake in these cells is 
probably via glut 2. The inability of D-fructose to 
inhibit the uptake in HIT-T15 cells is postulated to be 
due to the presence of an additional isoform for 
D-fructose in this cell line.
Although glut 2 may have a greater capacity to 
transport streptozotocin than the other isoforms it was 
discovered that streptozotocin also combined with glut 1 . 
Studies were carried out in which cytochalasin B binding 
to glut 1 in erythrocyte membranes was determined in the
8presence of streptozotocin. The streptozotocin was found 
to act as a competitive inhibitor of cytochalasin B 
binding.
The relationship between cytotoxicity and specificity 
for streptozotocin was examined in the HITm2.2 and 
RIN m5f cell lines The HITm2.2 cell line was found to be 
more sensitive to streptozotocin cytotoxicity than the 
RINm5f cell line. The cytotoxicity in the HITm2.2 cells 
was preventable by adding high concentrations of either 
D-glucose or 4,6-0-ethylidene-D-glucose to the incubation 
and growth media. It is postulated that the protective 
effect of 4,6-0-ethylidene-D-glucose is due to 
competition for entry of streptozotocin into the cells 
via the glucose transporter.
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1.1: The cellular composition of the pancreas.
The availability of in vitro islet cells isolated for 
experimental purposes have facilitated the study of beta 
cell metabolism. These islets are prepared from dissected 
pancreatic tissue which has been treated with 
collagenase. This procedure has enabled islet cells to be 
microdissected from other pancreatic tissue, with the aid 
of a microscope by careful microdissection 
(Lacy and Kostianovsky, 1967). Following microdissection 
these islet preparations can be maintained in cell 
culture for a limited time period. This method of islet 
extraction however, poses four major limitations. F o r - 
experimental purposes it is both difficult and time 
consuming to prepare even small quantities of islets. The 
islets cellular and hormonal characteristics have been 
reported to change as a result of the extraction 
procedure. Results from experiments with in vitro islets 
have demonstrated a reduction in the amount of secreted 
insulin and finally, preparations of islet cell cultures 
are documented to be contaminated by the presence of 
non beta cells. As a result of these main disadvantages 
scientists have attempted to develop a permanent cell 
line which retains the primary functions of the beta 
cell.
15
The pancreas is a large gland situated behind the 
stomach, between the spleen and duodenum. This organ has 
an elongated structure divided into the head, body and 
tail regions. Its external secretion (exocrine) contains 
digestion enzymes, while its internal secretion 
(endocrine) is composed of insulin, glucagon and 
somatostatin. The endocrine function of the pancreas is 
performed by the islets of Langerhans, which comprise 
only 1 to 2 % of the whole organ. These islets of 
Langerhans are clusters of cells found scattered 
throughout the pancreas with approximately one million 
cells present in the adult human. In man the islets are 
round to ovoid structures and have been shown to display 
some variation in their size (20 to 300 pm in diameter). 
In addition islets have been observed to have an 
extensive contact with the vascular system of the 
pancreas.
There are several types of endocrine cell within each 
islet. These are the beta cells which produce 
insulin, alpha cells which produce glucagon and the delta 
cells which produce somatostatin. The proportions of each 
type of cell are as follows. Each individual islet is 
normally comprised of 60 to 70 % beta cells and 
5 to 10 % delta cells.
In the last decade several pancreatic beta cell lines 
have been established from a variety of animal tissue 
sources. I have examined whether these cell lines can be
16
used as a model in which to study the function and 
morphology of the beta cell with respect to the transport 
of specific D-glucose analogues.
Organisms regulate their internal cellular 
environment by the exchange of physiological and chemical 
information with their external environment. This 
cellular regulation is achieved by a combination 
of co-ordinated intramembrane channels and carrier 
protein complexes. The D-glucose molecule provides a 
major source of metabolic energy. Therefore, a 
facilitative glucose transport system is present in all 
procaryotic and eucaryotic cells. In complex eucaryotic 
organisms with tissues which perform specific 
functions, there exists a family of glucose transporter 
proteins. These transporters have a primary sequence 
homology with one another and a tissue-specific pattern 
of expression. It has become apparent that this unique 
protein family, whose primary function is to transport 
D-glucose, has been modified to regulate the metabolism 
of D-glucose in each specific tissue.
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1.2: Development and characteristics of cultured 
pancreatic beta cells
1.2.1: The rat insulinoma cell line (RIN)
The RIN cell line was established by two collaborative 
scientific groups (Gazdar et a l .. 1980;
Lambert et a l ., 1972). Gazdar's group 
(Gazdar et a l ., 1980) were responsible for the 
establishment of the RIN cell line which originated from 
neoplastic rat islet tissue (Chick et a l ., 1977). In 
these cells, tumours were induced by subjecting inbred 
rats (New England Deaconess Hospital) to X-ray radiation. 
This irradiation produced transformed cells which were 
maintained by serial transplantation. After nine 
transplants of the neoplastic tissue, the tumour was 
finally heterotransplanted into an athymic nude mouse.
The cell lines were derived from either the rat or nude 
mouse transplants. They are called rat insulinoma cells 
derived from rat (RINr) and rat insulinoma cells derived 
from mouse (RINm).
RIN m5f cells have an epitheloid structure. The cells 
have been observed to double their population after a 
time period of 60 to 80 hours (Gazdar et a l ., 1980). The 
quantity of insulin secreted by the RIN m5f clone was 
found to be comparable to that of the parent RINm cell. 
Both of these cell types were recorded to have secreted
18
insulin at 8ng/10^ cells/24 hours (Gazdar et a l ., 1980). 
The secretion of insulin in response to a variety of 
secretagogues which include calcium, tolbutamide, 
theophylline and glucagon has been documented by various 
research groups (Bhathena et a l .. 1984). Praz et a l .. 
(1983) have demonstrated that the insulin content of RINm 
clones at higher passage numbers was equivalent to only 
1% of the total insulin measured in native rat beta 
cells.
Malaisse et a l ., (1986) studied the uptake of the
non-metabolised D-glucose analogue 3-0-methyl-D-glucose 
into the RIN m5f cell line. These transport experiments 
were performed at a range of different time periods and 
temperatures. This group proposed that
3-0-methyl-D-glucose was not fully equilibrated at any of 
the temperatures or time periods used in the study. The 
transport of D-glucose was shown to be inhibited by 
3-0-methyl-D-glucose. From these results obtained from 
their particular RINm cell line, Malaisse et_al., (1986)
postulated that there may be more than one sugar 
transporter protein in this particular cell line. This 
group also showed that cytochalasin B and phlorrizin were 
both potent inhibitors of transport. The observation of a 
loss of the ability of RIN cells to fully equilibrate 
D-glucose analogues across the cell membrane was 
contested by other groups. Trautman and Wollheim, (1987) 
demonstrated an efficient hexose transporter system
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displaying both a high capacity and low affinity for
3-0-methyl-D-glucose in RIN m5f cells. In this work the 
cells were equilibrated with 3-0-methyl-D-glucose and the 
Michaelis Menten constant (Km ) measured was found to be 
32 mM. This contrasts with an earlier finding of Malaisse 
et a l .. (1986) who reported a Km value of 2mM.
Thorens et a l ., (1988) found that a subclone of the 
RINm demonstrated a poor insulin secretory response to 
glucose. These investigators attributed this to the 
expression in these cells of the Glut 1 transporter. 
Recently Shibasaki et a l ., (1990) have developed a stable 
RINr cell line that over-expresses a complementary 
deoxyribose nucleic acid (cDNA) which codes for the 
erythrocyte type transporter (Glut 1). This cell line was 
observed to exhibit both an enhanced and constitutive 
secretion of insulin.
Certain RINr cell lines were reported to be resistant 
to the toxic effect of the diabetogenic compounds 
streptozotocin (STZ) and alloxan (A L X ) (Ledoux and 
Wilson, 1984; Sener and Malaisse, 1985). These 
investigators proposed that both STZ and ALX were taken 
up by the cell. Part of the resistance to the 
diabetogenic effects of both of these compounds has been 
attributed to their reduced transport into specific RIN 
cells (Sener and Malaisse, 1985). It was unclear from 
these studies whether this uptake was specifically via 
the glucose transporter.
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1.2.2: The Syrian hamster induced tumour cell line (HIT)
This cell line was established by Santerre et a l .,
(1981). These authors isolated islet cells from the 
Syrian hamster and treated them with 
ethylmethanesulphonate. Treated islets were then 
transformed and subsequently immortalised with simian 
virus-40 (SV40). Hamster induced tumour cells (HIT) were 
found to secrete insulin at a rate of 90 ng/ 10^ cells. 
The quantity of insulin released by HIT cells has been 
shown to vary with both passage and growth. This insulin 
release has been demonstrated to decline over an 11 month 
period up to passage 88 (Santerre et a l ., 1981;
Zhang et a l ., 1989). One of the parent subclones is the 
HIT—T15 m 2.2.2 often abbreviated to HIT m2.2 
(Edlund et a l ., 1985). In recent years both the parent 
HIT—T15 and the HITm2.2 subclone have been used as models 
in which to study the beta cell. These cell lines have 
also been demonstrated to secrete insulin in response to 
amino acids and a variety of other secretagogues 
(Hill and Boyd, 1985).
Some of the transport properties of the sugar 
transporter in HIT cells have been described by Meglasson 
(et a l .. 1986). This group demonstrated that
3-0-methyl-D-glucose was equilibrated within 20 minutes. 
This was considered a slow rate of transport when
21
compared with some other insulinoma cell lines. In these 
insulinoma cells 3-0-methyl-D-glucose equilibration was 
completed in 30 seconds. Ashcroft and Stubbs, (1987) 
confirmed that sugar transport into the HIT-TI5 cell line 
proceeded at a slow rate.
The classical sugar transport inhibitors phloretin 
and phlorrizin as well as the fungal inhibitor 
cytochalasin B, inhibited the utilisation of D-glucose 
within the HIT cell (Ashcroft et a l ., 1980). Ashcroft and 
Stubbs, (1987) also reported that neither L-glucose nor 
N-acetyl-D-glucosamine were transported by the HIT cell. 
D-galactose, 6-deoxy-D-galactose, goldthio-D-glucose and 
D-fructose sugars only competed weakly with D-glucose for 
entry into the cell. In these cells, insulin release in 
response to glucose was inhibited by both phloretin and 
cytochalasin B (Ashcroft and Stubbs, 1987). It has been 
observed more recently in HIT cells exposed to high 
glucose concentrations (Purrello et a l ., 1991), that both 
of the Glut 1 and liver/ pancreatic type transporter 
(Glut 2) mRNA levels are reduced. This mRNA reduction was 
associated with an impaired glucose induced insulin 
secretory mechanism. From this study Purrello 
(et a l .,1991), inferred that the HIT cell glucose 
transporter isoforms were regulated by the glucose 
molecule itself. Purrello proposed that a mechanism may 
exist whereby D-glucose down regulated its own transport.
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1.2.3: The mouse insulinoma cell line (MIN)
A recent transgenic method (Sarvetnick et a l ., 1988) has 
provided an experimental system which targets the 
expression of a specific oncogene in the transgenic 
mouse. As a direct result of this gene transformation, 
immortalised cell lines with differentiated phenotypes 
have been established.
The pancreatic beta cell lines which can be obtained 
by this strategy have retained many of the 
characteristics of the original beta cell. Two groups 
have reported upon the establishment of cell lines which 
have been derived from the SV40 T antigen transgenic 
mouse. One of these cell lines was the beta Tumour Cell 1 
(Efrat et a l .. 1988). These cells exhibited a high level 
of insulin secretion, while at the same time the cells 
demonstrated a high sensitivity to glucose stimulation.
In comparison another beta cell line derived from a SV40 
T antigen transgenic mouse (Gilligan et a l .. 1989), 
showed no response to any glucose stimulation.
Two specific cell lines have been established from 
insulinomas. These lines were obtained by the specific 
targeted expression of the SV 40 T antigen gene in 
transgenic mice. Two such tumour induced mice 
(IT 6 and IT 7) developed pancreatic insulinomas at 13 
weeks of age and the resulting murine cell lines were 
assigned the names MIN-6 and MIN-7. These lines were
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shown to produce significant quantities of both insulin 
and T antigen while they also retained the morphological 
characteristics of the pancreatic beta cell 
(Miyazaki et a l ., 1990). Of the two murine cell lines, 
the MIN-6 cells secreted insulin in response to glucose 
at a rate which was comparable to mice islets maintained 
in culture. However MIN-7 cells showed a negligible 
insulin secretion capacity. Miyazaki et a l ., (1990) have
reported that both of these cell lines contained mRNA 
which coded for the Glut 2 transporter. The MIN-6 cell 
line was shown to possess higher Glut 2 mRNA levels than 
MIN-7. The latter cell line was reported to contain large 
quantities of Glut 1 mRNA.
1.3: The erythrocyte transporter (Glut 1)
During the last decade, the advent of molecular 
biological techniques have enabled the family of membrane 
glucose transport proteins to be cloned. There are now 
known to be three main categories of sugar transporter. 
Characterisation into these groups is based on certain 
key observed functional differences. These categories are 
the sodium dependent, sodium independent and the insulin 
sensitive type of transporter. The erythrocyte, liver and 
beta cell transporters belong to the sodium independent 
category of this protein family.
Table 1.1: The five types of human glucose transporter 




(no. of amino 
acids)




(a) Facultative glucose transporters
(1) GLUT 1 492 Fetal tissues, brain, kidney 1
(Erythrocyte, and colon
HepG2. brain)
(2) GLUT 2 524 Liver, p-cell, kidney 3
(Liver) and small intestine
(3) GLUT 3 496 Many tissues including brain, 12
(Fetal muscle) placenta and kidney
(4) GLUT 4 509 Skeletal muscle, heart 17
(Muscle/adipocyte, and adipocytes
insulin-regulatable)
(5) GLUT 5 501 Small intestine 1
(Small intestine)
(b) Na+/glucose co-transporter or symporter




It is now apparent that there are a family of genes 
which are located on different chromosomes. These genes 
code for a variety of sugar transport proteins which are 
expressed in the types of cell shown in Table 1.1. To 
date at least five different transporter isoforms have 
been isolated and their respective amino acid sequences 
have been deduced from their cloned cDNA's. These protein 
isoforms are designated Glut 1 to 5.
Glut 1 has been the most extensively studied of all 
the transporters. The Glut 1 transporter is proposed to 
be an integral membrane protein of between 45 to 55 kDa. 
Mueckler et a l .. (1985) screened the gene library with a 
specific antibody raised against a partially purified 
Glut 1 protein. The Glut 1 sequence coded for a 492 amino 
acid protein which was similar but not identical to a 
partial sequence from an earlier purified preparation 
reported by Baldwin et a l .. (1982). HepG2 cells, 
erythrocytes and rat brain were shown to contain the Glut 
1 protein (Birubaum et a l ., 1986). The brain Glut 1 
sequence was 98 % identical to the Glut 1 sequence 
obtained from the HepG2 cell line.
The mRNA coding for the Glut 1 transporter has been 
subsequently identified in most tissues including fetal 
tissue and the placenta. In adults, Glut 1 mRNA was found 
in the brain, kidney, colon and most cultured cell lines. 
Levels of the Glut 1 mRNA in the liver and skeletal
Figure 1.1: A model showing the proposed orientation of 
the facilitative glucose transporter within the plasma 
membrane.
There are twelve transmembrane helices which are 
shown as outlined boxes, numbered M1 to M12. There is a 
potential attachment site for a N-linked oligosaccharide 
in the extracellular loop connecting helices M1 and M2. 
This oligosaccharide is present in each of the five 
mammalian facilitative glucose transporter isoforms. 
Identical amino acids in the human Glut 1 to Glut 5 are 
indicated using their single letter abbreviation 
(D, E; F, Y, W; I, L, V, M; K, R; N, Q; and S, T). 
Chemically similar residues are denoted by the black 
circles. The N- and C-terminal domains as well as the 
exofacial loop between M1 and M2, differ in both sequence 
and size between the transporter isoforms 





muscle tissues were however found to be low 
(Fukumoto et a l .. 1988a).
Mueckler et a l ., (1985) proposed a two dimensional 
model for the orientation of the sugar transporter within 
the membrane. This was based on a sequential arrangement 
of the amino acids according to their hydrophobicity as 
outlined in Figure 1.1. The structure of the sugar 
transporter is reputedly organised into three main 
domains which are outlined below:
Domain 1 consists of twelve alpha helices each 
spanning the lipid bilayer. Both the amino and carboxyl 
end terminal amino acids are proposed to be located 
within the cytoplasm. Domain 2 comprises 65 highly 
charged hydrophilic amino acids situated endofacially. - 
Domain 3 is a 33 amino acid portion situated exofacially. 
Domain 3 contains the asparagine amino acid which is 
linked to an oligosaccharride when the protein is in its 
native state.
Studies using peptide specific antibodies carried out 
by Davies et a l .. (1987) have confirmed a number of
salient features of the transporter model which are 
outlined in figure 1.1. Further information about the 
characteristics of the transporter have been confirmed by 
epitope mapping studies using proteolytic digestion and 
specific antibodies (Cairns et a l ., 1984). Trypsin was 
used to cleave the cytoplasmic face of Glut 1 . This 
treatment resulted in the production of two membrane
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fragments. One of these cleaved fragments contained the 
asparagine-linked oligosaccharride while the other 
fragment contained the cytochalasin B binding site. 
Spectroscopic studies performed by Alvarez et a l .. (1987)
have also confirmed that Glut 1 possess mainly alpha 
helices together with some random coil and beta sheet 
structure. In addition, the extracellular protein domains 
have been shown to contain some alpha helical structure 
(Cairns et a l ., 1987).
1.3.1: Reconstitution studies and the covalent labelling 
of the Glut 1 Transporter
Studies have been performed in which erythrocyte Glut 1 
has been purified and reconstituted by using surfactants 
and chromatographic techniques (Kasahara and Hinkle,
1977). In 1981 Wheeler and Hinkle (1981), used purified 
erythrocyte Glut 1 and showed that sugar uptake was 
inhibited by cytochalasin B, mercury chloride and 
phloretin. In addition the purified transporter from 
erythrocytes has been shown to bind 0.5 moles of 
cytochalasin B per mole of protein (Sogin and Hinkle,
1978). Baldwin et a l ., (1982) purified Glut 1 from 
erythrocytes using octylglucoside and found that 
0.7 moles of cytochalasin B bound per mole of 
transporter, indicating a possible 1:1 stoichiometry. 
Further work using reconstitution studies with liposomes
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has shown a functional protein which mediates D-glucose 
uptake, with kinetics that are proposed to be 
indistinguishable from the transporter in intact cells 
(Carruthers and Melchoir, 1984).
Deziel et a l . , (1984) has shown how covalent labels 
can be used to characterise Glut 1. These labels include 
glycosylisothiocyanate, 1-fluoro-2,4-dinitrobenzene and 
cytochalasin B. The latter can be used as a specific 
photolabel. Following irradiation with ultraviolet light 
cytochalasin B can be used to label the transporter 
endofacially with an 8% efficiency (Deziel et a l ., 1984).
Exofacial labelling reagents have been developed with 
a photoreactive group at position 4 on the sugar ring. 
Bis-hexoses were synthesized. These labelled the 
exofacial binding site of the transporter. One key 
specific exofacial label, the azidosalicoyl derivative of 
bis-D-mannos-4-yloxy-2-propylamine (ASA-BMPA) has been 
shown to label the Glut 1 transporter peptide 
(Holman et a l ., 1986).
Cytochalasin B photolabelling followed by proteolytic 
fragmentation has been used to produce a map of the 
inside and outside binding sites as illustrated in figure
1.2 (Holman and Rees, 1987). The cytochalasin B binding 
site has been specifically assigned to the inside of the 
hydrophobic alpha helical membrane span 10 (H-10), with 
tryptophan 412 reputed to be the labelled residue 
(Cairns et a l . , 1987). The sugar binding core of the
Figure 1.2: The proposed location of the exofacial 
ASA-BMPA and endofacial cytochalasin B-binding sites on 
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transporter is proposed to possess both an internal and 
an external (ASA-BMPA labelled portion) binding site. A 
transmembrane glucose channel is proposed to be located 
between H-7 and H-10.
1.3.2: The hvdroaen bonding specificity of the Glut 1 
transporter
Studies investigating the hydrogen bonding specificity 
between glucose and the transporter have been performed 
by Lefevre (Lefevre and Marshall, 1958). These 
investigators have proposed that the transporter 
preferred the chair conformation of the sugar. Kahlenberg 
and Dolansky, (1972) inferred that several hydroxyl 
groups upon the sugar ring were involved in binding. This 
was confirmed by Barnett et a l ., 1973. This group studied 
analogues in which hydroxyl groups were replaced with 
hydrogen and fluorine at carbons 1, 2, 3, 4 and 6. These 
authors demonstrated that all of the sugar analogue 
derivatives bound to the protein in the beta pyranose 
form. Hydroxyl groups on the 1, 3 and 6 carbons were also 
proposed to be required for binding to the transporter 
(Barnett et a l . . 1973). Barnett et a l ., (1975) inserted 
bulky hydrophobic substituents onto D-glucose at the 1, 4 
and 6 positions and proposed the existence of a protein 
pocket. It has been shown that when glucose approaches 
the transporter exofacially or endofacially, carbon 1 and
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6 interacts first with the inward or outward binding 
conformer respectively as in figure 1.3. The hydrogen 
bonds at the binding site may be provided by helices 7, 8 
and 11 . The hydrophobic cleft may be composed of helices 
9 and 10 (Silverman, 1991).
Data from hydrogen exchange experiments have been 
used to predict that ligand binding would collapse a 
water filled channel (Harvey et a l .. 1976). Alkyl groups 
substituted for the hydroxyls upon the sugar ring were 
proposed to reduce the binding of glucose by steric 
interference.
1.3.3: The mechanism and kinetics of glucose binding to 
the Glut 1 transporter site
D-glucose is transported by a passive diffusion process. 
The Km for D-glucose uptake has been shown to be 1.6 mM 
(Block, 1974; Appleman and Leinhard, 1985; Lin and 
Spudich, 1974). Lowe and Walmsley, (1986) proposed that 
the transporter adopts both mutually exclusive inward and 
outward facing conformations. This idea has been 
supported by Holman and Rees, (1987) who used thermolysin 
cleavage to promote cytochalasin B binding and exclude 
the ASA-BMPA label from binding. In this study 
cytochalasin B was shown to bind to the inward-facing 
cleavage-susceptible conformer. Cytochalasin B 
competitively inhibits D-glucose efflux and therefore
Figure 1.3: A diagrammatic representation of the proposed 
binding of the pyranose substrate to the hydrophobic 
cleft of the erythrocyte glucose transporter (Silverman, 
1991 ) .
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binds to the inward-facing conformer. Cytochalasin B was 
shown to inhibit the influx of D-glucose.
Further evidence which supports the alternate 
conformer model was provided by ligand binding studies 
showing that the inward and outward conformers 
were mutually exclusive. In this work
4,6-0-ethylidene-D-glucose was shown to bind exofacially 
and to prevent cytochalasin B binding (Deves and Krupka, 
1978; Gorga and Leinhard, 1981).
Spectroscopic studies have revealed that D-glucose, 
cytochalasin B and 4,6-0-ethylidene-D-glucose all 
attenuate fluorescent emissions (Pawagi and Deber, 1990; 
Gorga and Leinhard, 1985). This has been attributed to a 
conformational change due to a tryptophan transition from 
a hydrophilic to a hydrophobic environment. This change 
possibly involves tryptophan 363, 388 or 412. Tryptophan 
388 was proposed to be the candidate due to its proximity 
to the dynamic transport segment shown in figure 1.2. A 
transient fluorescence due to 4,6-0-ethylidene-D-glucose 
binding was attributed to a transporter reorientation 
from the inward to the outward facing conformer 
(Appleman and Leinhard, 1985).
Evidence gathered from pre-steadystate stopped-flow 
kinetic experiments (Appleman and Leinhard, 1985) have 
supported an alternating conformational model for 
D-glucose transport (figure 1.4).
Figure 1.4: A schematic representation of the kinetic 
model of the glucose transporter. The k's represent rate 
constants for the substrate and protein (receptor) 
dissociation. G and T refer to the glucose and 
transporter concentrations. T0 represents the outward 















In the alternating conformation model for transport 
the protein is believed to oscillate between two specific 
conformations (Lowe and Walmsley, 1986). These are both 
an extracellular and an intracellular conformer state. 
Upon occupation of the binding site, a conformational 
change will occur resulting in the translocation of the 
bound glucose across the membrane.
A second model proposes that the two substrate 
binding sites are simultaneously present 
(Carruthers, 1986). This model is a more complex kinetic 
analysis. If however the carriers exist as oligomeric 
proteins in their native state within the membrane then 
complicated kinetic behaviour may take place.
1.4: The liver type glucose transporter (Glut 2)
The liver plays a crucial role in maintaining blood 
glucose homoeostasis. After feeding it absorbs glucose 
for the synthesis and storage of glycogen. The liver can 
synthesize glucose from amino acids. In the liver insulin 
increases glucose utilisation but not its uptake. This 
contrasts with fat and muscle tissue where uptake is 
stimulated by insulin (Calderhead and Leinhard, 1988).
Biochemical and molecular biological studies has 
shown a distinct type of liver transporter (Glut 2) with 
Km s for D-glucose and cytochalasin B ten fold higher than 
Glut 1 (Axelrod and Pilch, 1983). Glut 2 has been shown
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to be present in the beta cell (Fukumoto et a l ., 1988b; 
Thorens et a l ., 1988; Permutt et a l ., 1989).
Glut 2 is unique as it releases glucose during 
fasting. It also has a high Km for D-glucose 
(Elliot and Craik, 1982). This high Km of glut 2 ensures 
that the transporter operates in the linear portion of 
the substrate velocity curve and that the glucose flux 
will change linearly according to the blood glucose 
level. cDNA clones have been isolated which code for both 
the human and rat Glut 2 proteins. The Glut 2 sequence 
possesses a 55.5 % identity to Glut 1, with an 82 % 
identity between the human and rat transporters. Analysis 
of the predicted primary structure has indicated that 
Glut 2 possesses the same topological organisation as 
Glut 1. Expression of Glut 2 in an Escherichia coli 
(E. coli) defective glucose transport strain has shown 
that the protein is a transporter with the expected 
stereospecificity (Thorens et a l .. 1988).
1.5: The pancreatic islet beta cell or Glut 2 transporter
Heilman (et a l ., 1971) provided the initial evidence for 
the mediated transport of D-glucose into the beta cell. 
Sugar uptake into freely suspended islets was shown to 
reach equilibrium within 1 minute (Lernmark et a l .. 1975; 
Lernmark et a l ., 1976). Gorus et a l . . (1984) have shown 
that 3-0-methyl-D-glucose is transported at a rate of
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402 pmol of sugar per minute per cell. Beta cells have 
been shown to equilibrate 3-0-methyl-D-glucose within 2 
minutes in contrast to the alpha cells where full 
equilibration did not occur.
In 1989 Orci et a l .. (1989) performed a study of the 
Glut 2 topography and observed that the transporter was 
confined to specific domains within the plasma membrane 
of islets. This group, using data from labelled electron 
microscopy techniques, have indicated that the 
transporter is responsible for the flow of D-glucose 
within the islet. It was proposed that Glut 2 appears to 
direct glucose to regions distal from the capillaries. 
3-0-methyl-D-glucose has been shown to be 90% 
equilibrated across the dispersed islet cell within an 
incubation time of 1 minute (Johnson et a l ., 1990 b). 
Kinetic analysis has revealed that glucose transport in 
islets occurs via two kinetically distinct components.
The first component has a Km of 17mM which was attributed 
as being associated with the presence of Glut 2. The 
other component has a Km of 1.4 mM and is probably 
associated with the presence of Glut 1 . In this work it 
was also demonstrated that distinct cytochalasin B 
binding constants existed which were attributable to 
Glut 2 and Glut 1. This data suggested that Glut 2 was 
present in higher amounts than Glut 1 .
Chen (et a l ., 1990) investigated whether the Glut 2 
protein was constitutively expressed or regulated in the
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beta cell. In animal studies, these authors have recorded 
that after the induction of hypoglycaemia, the Km for 
3-0-methyl-D-glucose is reduced. There is an associated 
reduction in the Glut 2 mRNA level. It was inferred the 
expression of Glut 2 could be regulated by the 
circulating blood glucose level. Yasuda (et a l .. 1992) 
also confirmed this. Under hyperglycaemic conditions the 
Glut 2 message was shown to increase. In cultured islets, 
Glut 2 mRNA levels were shown to increase following 
incubation at high D-glucose, D-mannose and D-fructose 
concentrations (Asano et a l ., 1992). In this study 
however, 3-0-methyl-D-glucose, 2-deoxy-D-glucose and 
D-sucrose had no effect.
A detailed kinetic investigation of the Glut 2 
transporter was performed by Gould (et a l .. 1991). His 
laboratory have successfully expressed Glut 2 in the 
Xenopus oocyte expression system. They measured 
3-0-methyl-D-glucose and 2-deoxy-D-glucose transport. 
2-deoxy-D-glucose uptake was found to be inhibited by 
D-glucose but not L-glucose and D-galactose. D-mannose 
and D-fructose were also demonstrated to be transported 
by human Glut 2. Gould also obtained Km values for Glut 2 
with respect to transported 3-0-methyl-D-glucose (42 mM),
2-deoxy-D-glucose (13 mM) and D-glucose (66 mM) 
respectively. These kinetic values were shown to be 
different to those of Glut 1. Sener (et a l ., 1984) have 
also shown that the beta cell transports D-fructose.
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A number of cell lines have also been reported to 
contain the Glut 2 transporter. A study of transporter 
gene expression in a Syrian Hamster pancreatic beta cell 
line has revealed the existence of both Glut 1 and Glut 2 
mRNA (Purrello, 1991). When this cell line was maintained 
in tissue culture at a high glucose concentration the 
mRNA levels for Glut 1 and Glut 2 were found to be 
reduced. This effect was correlated with a reduction in 
the cells insulin secretion capability. Miyazaki 
(et a l . , 1990) generated a cell line (MIN-6) that 
retained the ability to secrete insulin in response to a 
glucose challenge. Here Glut 2 was shown to be the major 
transport protein. Evidence for this was based on the 
presence of Glut 2 mRNA in these MIN-6 cells.
1.6; Glut 2 transporter dysfunction and a possible link 
with diabetes
In the Western Hemisphere diabetes is estimated to affect 
2% of the total population. From this populace total, 10 
to 25% consists of a clinically defined specific 
autoimmune disorder which destroys the insulin secreting 
beta cells. This disorder is called Type 1 or insulin 
dependant diabetes mellitus (IDDM). As the 
"insulin dependent" name infers patients suffering from 
this condition require insulin replacement therapy. Such 
therapy will thus prevent the advanced diabetic symptoms
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of ketoacidosis, coma and death. In the remaining 75 to 
90% the diabetes is somewhat attenuated and 
hyperglycaemia is caused by a failure of beta cells to 
meet increased demands for insulin (Type 2 or Non-insulin 
Dependent Diabetes). The reason why these cells cannot 
meet this demand for insulin is as yet undefined. Table
1.2 outlines the primary symptoms associated with these 
two disease states.
Some evidence linking Diabetes directly to a defect 
in the transport of glucose has originated from antibody/ 
islet transport experiments. In these studies it was 
found that within 24 hours of the onset of autoimmune 
diabetes, D-glucose transport is reduced by 90% (Tominga 
et a l .. 1986). This loss in transport activity has been 
shown to be accompanied by the reduction of glucose 
stimulated insulin secretion. In this study however, a 
specific response to arginine is still retained. From 
this and other such observations it has been proposed 
that a defect in the transport function, irrespective of 
the cause, would impair the beta cells ability to respond 
to hyperglycaemia.
Chen (et a l .. 1990) reported that the Glut 2 protein 
is down regulated by chronic hyperinsulinemia. In this 
work, at concentrations of glucose above normal fasting 
levels, glucose transport was impaired by the absence of 
Glut 2. This is further evidence that an absence or 
impairment of Glut 2 would result in beta cells being
Table 1.2: A comparison between the two clinically 
defined forms of diabetes mellitus. These are type 1 
insulin dependent diabetes mellitus (IDDM) and type 2 
non-insulin dependent diabetes mellitus (NIDDM) 
(Unger, 1991 ) .
Characteristic IDDM NIDDM
Age at onset Childhood and 
young adulthood
Middle and old age
Race Predominately Caucasians All races





Mechanism Autoimmune destruction Unknown
Initial Insulitis; reduction Litde or none
pathology in p-cell mass
a^te pathology Absence of 3 cells; Amyloid deposition;
increase in a  and 5 cells fibrosis; 3-cell mass 
normal or moderately 
reduced
First functional Decrease in glucose- Decrease in glucose-




unable to respond to blood glucose increases in excess of 
normal fasting levels. This would result in the 
continuation of postprandial hyperglycaemia, the first 
clinical symptom of diabetes.
Immunoglobulins isolated from the sera of recently 
diagnosed IDDM patients have been demonstrated to 
interfere with both beta cell glucose transport 
(Johnson et a l ., 1990a) and insulin secretion 
(Kanutsuna et a l ., 1983). Dispersed islets, which have 
been incubated with diabetic antisera, exhibit a 
reduction in the uptake of 3-0-methyl-D-glucose when 
compared to normal control sera. From this observation it 
has been inferred that serum antibodies from diabetic 
patients will react with either Glut 2 or a putative 
protein which influences the Glut 2 function.
The levels of Glut 2 are also reduced in the beta 
cells of animals which have undergone autoimmune 
destruction of the pancreas. Orci et a l ., (1990b) have 
made observations from these animal models at the onset 
of diabetes and found that only 48 % of the surviving 
beta cells expressed Glut 2. In addition to this there 
are many other reports of immunoglobulins from diabetics 
which inhibit glucose stimulation of insulin release. The 
presence of anti-Glut 2 antibodies was not determined in 
these preparations (Kitagawa et a l .. 1990).
In Type 2 diabetes there is no consistent reduction 
in the number of beta cells within the islet. A loss of
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glucose stimulated insulin secretion at the onset of 
fasting hyperglycaemia occurs without a parallel loss in 
the arginine response. Unger, 1991 proposed that this was 
due to a defective high capacity glucose transporter. 
NIDDM animal models (inbred colony of a glucose 
intolerant Zucker fatty rats) have been used 
(Clark et a l .. 1983) to examine this hypothesis. This 
work has documented that in prediabetic rats, the Glut 2 
levels are normal but are undetectable in the severe 
diabetic animals (Johnson et a l .. 1990c;
Orci et a l ., 1990a). The presence of some highly charged 
amino acid (amino terminal) residues at the endofacial 
side of Glut 2 (Newgard et a l ., 1990), may facilitate an 
interaction between Glut 2 and the glucokinase enzyme.
Oka et a l ., (1990b) demonstrated that in 
streptozotocin-induced-diabetic rats, the Glut 2 
transporter was increased two fold in liver membrane 
homogenates when these were compared to the normal 
controls. Upon treatment with insulin both the levels of 
the transporter and its mRNA were reduced in liver cells. 
Experimental rats injected with STZ have been 
demonstrated to develop NIDDM, while at the same time 
these rats also exhibited a reduced expression of the 
Glut 2 isoform in beta cells (Thorens et a l .. 1990a and 
1990b).
39
1.7: A background to the diabetogenic drug streptozotocin
Streptozotocin (STZ) is a broad spectrum antibiotic 
(Vavra et a l ., 1960) and an antitumour agent, isolated 
originally from the bacterium Streptomyces Achromogenes. 
It is a 2-deoxy-D-glucose analogue with the cytotoxic 
moiety N-nitrosomethylurea (MNU) attached. When STZ is 
administered to animals it specifically destroys the beta 
cells and renders the animal diabetic. The structures of 
both STZ and MNU are shown in figure 1.5.
Schein et a l ., (1973) studied the diabetogenic 
activity of STZ in islets and correlated its use with a 
reduced pyridine nucleotide concentration. STZ was found 
to inhibit radio-labelled nicotinamide incorporation into 
the nicotinamide adenine dinucleotide (NAD) molecule. 
Nicotinamide administration to various experimental 
animals has been shown to reverse the action of STZ. An 
observed partial block in NAD synthesis with STZ (Schein 
et a l ., 1973) was thought to be due to an inhibition of 
the polyadenosine diphosphoribose synthetase 
(Uchigata et a l .. 1982). Lazarus and Shapiro (1973) 
demonstrated that NAD partially prevented diabetes. This 
partial protection effect was possibly due to the poor 
uptake of the NAD molecule into whole cell islets. STZ 
and MNU were both observed to produce reduced hepatic NAD 
concentrations. MNU was also reported to be
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non-diabetogenic in islets when it was exposed at 
physiological concentrations (Schein, 1969). These two 
compounds both exhibited a tissue specific pattern of 
transport and the uptake of STZ into the islets was 
reported to be four fold greater than MNU 
(Anderson et a l ., 1974), MNU is a nonpolar lipid soluble 
molecule which will passively diffuse across the 
membrane. In streptozotocin (STZ), the combination of a 
glucose moiety and the MNU moiety may have produced a 
structure which facilitates its recognition by the 
transporter. Once inside the cell the nitrosomethylurea 
side chain would reduce the level of intracellular NAD 
through the lesion of the target cells DNA 
(Uchigata et a l .. 1982). This mechanism has been proposed 
to involve the methylation of the DNA which would then 
require repair via the key enzyme polyadenosine 
di-phosphoribose synthetase. This enzyme uses NAD as a 
substrate and therefore this may account for the lowering 
of the intracellular NAD concentration. This process will 
affect the islet cell function, by an inhibition of 
proinsulin synthesis which may in turn destroy the beta 
cell (Uchigata et a l ., 1982; Yamamoto et a l .. 1981). 
Evidence which supported the above theory has come from 
Sandler and Swenne, (1983). These authors performed a 
series of studies with compounds which were demonstrated 
to inhibit the synthetase enzyme, while at the same time 
protecting against the STZ-induced depression of the
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bio-synthesis of insulin. The mechanism for the proposed 
action of STZ and another diabetogenic agent alloxan 
(ALX) are outlined in figure 1.6.
STZ has been shown to affect the beta cell in other 
reversible ways. These functional defects include a 
decrease in glucose stimulated oxygen uptake, glucose 
oxidation and insulin secretion. These effects are 
observed when the beta cell is challenged with D-glucose 
(Gunnarsson et a l .. 1974). Such effects have also been 
seen (but were attenuated) when beta cells were exposed 
to N M U . Gunnarsson et a l .. (1974) have suggested that a 
diminished toxicity with the MNU may indicate that the
2-deoxy-D-glucose moiety is important in facilitating its 
transport into the cell.
1.7.1: Evidence for a membrane recognition site for the 
glucose moietv in the streptozotocin molecule
A glucose recognition site on the pancreatic beta cell 
membrane which recognises STZ has been identified. The 
effects of STZ have been demonstrated to be inhibited 
by specific sugar analogues, namely 3-0-methyl-D-glucose 
and 2-deoxy-D-glucose, but not by alpha-0-methyl-3-0- 
methyl-D-glucose. Kawada et a l .. (1987) found that 
specifically substituted sugar analogues of STZ, such as 
those with D-mannose and D-galactose instead of D-glucose 
are nondiabetogenic. The analogue 4,6-0-ethylidene-D-
Figure 1.6: A hypothetical mechanism to account for the 
protection of islet beta cells against the action of 
Streptozotocin. As indicated by the shaded 
lines, superoxide dismutase and catalase may protect 
against alloxan-induced DNA strand breaks 
by preventing the formation of OH radicals.
Poly (ADP-ribose) synthetase inhibitors may also protect 
against alloxan or Streptozotocin-induced depression of 
proinsulin synthesis by the inhibition of NAD degradation 
(Uchigata et a l .. 1982).
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glucose, which protects against STZ toxicity, has been 
shown to be a non transported inhibitor. This analogue 
has also been demonstrated to bind to the extracellular 
surface of the glucose transporter from human erthrocytes 
(Barnett et a l .. 1975), rat adipocytes
(Holman et a l ., 1981) and the blood brain barrier of rats 
(Dick et a l ., 1984). These studies provide indirect 
evidence for the presence of a glucose transporter on the 
beta cell membrane which transports STZ. A nonmetabolised
3-0-methyl-STZ analogue has also been demonstrated in 
rats, to be as potent as the parent STZ molecule 
(Kawada et a l ., 1986).
Ledoux and Wilson, (1984) reported that an active 
glucose sensing mechanism may be necessary to enhance STZ 
cytotoxicity in both normal and neoplastic beta cells. 
Certain RIN cell lines were found to be resistant to STZ 
damage compared with beta cells. These RIN cells were 
also shown to have attenuated levels of glucose-induced 
insulin secretion. In addition to the above studies, STZ 
was shown to cause both a dose and time dependent damage 
of the DNA of this RIN cell line. Similar studies with 
the MNU molecule in RIN cells demonstrated an attenuation 
in its diabetogenic activity. Ledoux and Wilson (1984) 
speculated that STZ entered the cell by the process of 
passive diffusion, with the overt cell toxicity being 
avoided in the cells because of a low uptake of the drug. 
Overall it has been inferred that the effect of the
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glucose moiety upon the STZ molecule appears to 
facilitate its transport into normal beta cells. The 
glucose moiety is therefore proposed to be important for 
the selectivity of its action (Anderson et a l .. 1974).
1.7.2: Toxicity of strentozotocin through the generation 
of free radicals
The mechanism whereby STZ stimulates the generation of 
peroxide radicals within the cell, which ultimately leads 
to the fragmentation of that cells DNA has been 
investigated by Takasu et a l .. (1991). These authors 
proposed that within the target beta cell, diabetes may 









When STZ was injected into an animal it appeared to 
accumulate within the islet very rapidly 
(Tjalve et a l ., 1976). To study the formation of free 
radicals within the beta cell, the spectrographic
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technique of electron spin resonance spectroscopy has 
been used (Nukatsuka et a l ., 1988). STZ has been shown to 
increase the electron spin resonance signal resulting 
from the generation of oxygen radicals. It is known that 
beta cells contain a high xanthine oxidase activity and a 
low superoxide dismutase activity. The cytotoxic effects 
of STZ may therefore be associated with the generation of 
free radicals (peroxide and oxygen), either directly due 
to STZ or via stimulation of the xanthine oxidase enzyme.
1.8: Aims of the thesis
1 . To perform a kinetic investigation into the D-glucose 
transport system of specific beta cell lines using 
6-deoxy-D-glucose and D-fructose as substrate's. To 
determine whether the expressed transport system is of 
the Glut 2 type. To define whether other transporter 
types are present in these cell lines and to evaluate 
whether these cell lines constitute an accurate model of 
the glucose transport properties of the beta cell.
2. To investigate the specificity of the transport 
protein using the four different cell lines and observe 
any differences between these systems and other fully 
characterised transport systems. To look at the 
relationship between the toxicity of streptozotocin and 
the specificity of its binding to islet beta cell lines. 
To work towards an elucidation of how the drug induces
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chemical diabetes and also investigate the possibility of 
a specific glucose recognition site for glucose sensing.
3. To synthesize a radiolabelled analogue of the 
diabetogenic drug streptozotocin and study the kinetics 
of its uptake into pancreatic beta cell lines. To 
establish whether a specific transport protein exists for 
the drug. A determination of whether streptozotocin 
utilizes the same transport system as 6-deoxy-D-glucose 
and D-fructose.
CHAPTER 2 MATERIALS AND METHODS
2.1: Materials
All the non-radiolabelled sugars and streptozotocin were 
supplied by Sigma Chemical company, Poole, Dorset. 
Reagents for the organic reactions were supplied by 
Aldrich Chemical company, Gillingham, Dorset. Ion 
exchange resins were supplied by BDH Ltd., Poole, Dorset 
and Whatmann Ltd., Maidstone, Kent. Silica gel-G 60 and 
silica gel-G 60-F preformed thin-layer chromatography 
plates were from Merck, BDH, Poole, Dorset. The 
scintillation fluid was Optiphase which was supplied by 




2-deoxy-D-(-^H)-glucose (6.6Ci/mmol), D-(U-^C)-fructose 
(304 mCi/mmol), D-(U-^C)-sucrose ( 300mCi/mmol),
D-1-(U-^C)-glucosamine (58.7 mCi/mmol) and 
(^H)-cytochalasin B ( 295mCi/ mmol) were supplied by 
Amersham International U.K. 6-Deoxy-D-(JH )-glucose 




In all buffers the final pH was adjusted with 6M NaOH or 
HCL where apppropriate. 4-(2-Hydroxyethyl)-1- 
piperazineethane-sulphonic acid (HEPES) supplemented 
salts buffer was prepared according to the following 
protocol.
HEPES (10mM), NaH2PC>4.2H20 (2.5 mM), NaCl (130 mM),
KC1 (5mM), MgS0 4 .7H 20 (1mM) and CaCl2.2H20 (2mM) were all 
dissolved in 1 litre of deionised water. The buffer was 
adjusted to a final pH of 7.4.
Phosphate buffered saline (PBS) and calcium magnesium 
free PBS tablets were purchased from Oxoid, ltd. A PBS 
buffer was also prepared according to the following 
protocol. Na 2HPC>4 (12.5mM) and NaCl (154 mM) were 
dissolved in 1 litre of distilled water. This buffer had 
its final pH adjusted to 7.2.
A haemolysing buffer was prepared with Na 2HPC>4 (5mM), 
Ethylene diamine tetra acetic acid (EDTA) (1mM) and 
5 y.1 of Phenyl methoxysulphonalfluoride (PMSF) 
solubilised in Dimethylsulphoxide (DMSO)
(10 mg PMSF: 50]il DMSO). The final volume of this buffer 
was made up to one litre with distilled water. The final 
pH of this haemolysing buffer was adjusted to 7.8.
A copper tartrate carbonate mixture was prepared 
essentially as follows. Sodium potassium tartrate (2%), 
copper sulphate (1%) and sodium hydroxide (1M) were all
added to distilled water to provide a stock solution. 
Then the above stock solution was added to a 2% sodium 
carbonate solution to provide the final buffer.
2.1.3: Cultured pancreatic beta cell lines used
Four cultured beta cell lines were used in the work 
described in this thesis. The HIT-T15 cell line (1990) 
was provided by Dr. R. F. Santerre, Boston (MIT), U.S.A. 
The HITm2.2 cell line (1989) was obtained from 
Dr. D. Boam, Birmingham Medical School, Birmingham. The 
RINm5f cell line (1989) was provided by Dr. W. Atkins, 
University of Aston, Birmingham and the MIN-6 cell line 
(1991) was provided by Dr. Y. Oka, Osaka, Japan. All of 
these cell lines were obtained with the original passage 
number less than 7.
2.1.4: Tissue culture items used
All of the mediums and supplementary materials were 
supplied by Flow Labs, Irvine, Scotland.
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2.2: Methods
2.2.1: Tissue culture procedures. The defrosting and 
crvopreservation of the cell lines
HITm2.2 and the RINm5f cell lines (passage 5) were 
maintained in a Rosewell Park Memorial Institute (RPMI) 
1640 supplemented tissue culture medium. These cells were 
grown as a monolayer in 9 cmJ petri dishes. RPMI 1640 
medium was supplemented with 10% heat inactivated foetal 
calf serum (FCS), 1% L-glutamine (200 mM stock) and a 
2% penicillin streptomycin antibiotic stock 
(5000 IU/ml:5000g/ml). These cell lines at an appropriate 
density of 7x 10^ per cryotube were preserved in FCS and 
DMSO (9: 1 v/v). Each cryotube which contained cells was 
cooled in the vapour phase of liquid nitrogen with an 
appropriate slow cooling unit. While the cells were 
cooled it was important that the temperature decreased at 
a precise rate of -1°C per minute until they reached 
-80°C. After approximately 20 hours the cryotubes 
containing the cells were transferred to the liquid phase 
of liquid nitrogen. Here HITm2.2 and RIN m5f cells were 
stored at an approximate temperature of -196°C until they 
were required for experiments. The HITm2.2 and RINm5f 
cells were grown in a standard LEEC incubator at 37°C. 
This incubator contained a humidified gaseous mixture 
which was comprised of 95% air/ 5% CO2 .
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The HIT-T15 cell line (passage 4) was cultured as a 
monolayer in a HAMS-F12 complete medium. This medium was 
supplemented with 10% FCS, 1% L-glutamine 
(200 mM stock) and 2% of a penicillin streptomycin 
(5000 IU/ml: 5000g/ml) antibiotic. HIT-T15 cells were 
cryopreserved following exactly the same slow-cooling 
protocol described above. The HIT-T15 cell line was 
frozen in a Hanks balanced salts solution containing 
0.5 % lactalbumin, new-born calf serum (NCS) and DMSO 
(8: 1 v/v). These cells were grown and maintained in a 
LEEC incubator at 37°C. The atmosphere inside the 
incubator was a mixture of 95% air and 5% C02- HIT-T15 
cells reached confluence at a density of 5x 10^ cells per 
dish. These cells were preserved at this density and then 
the confluent cells were split (1: 2) and grown at a
lower density for a time period of 5 days.
The MIN6 cell line (passage 6) was grown and 
maintained in a Dulbeccos Modified Eagles medium (DMEM). 
This medium was supplemented with 20% FCS, 1% L-glutamine 
(200mM stock), 2% of a penicillin streptomycin stock 
antibiotic (5000 IU/ml: 5000g/ml) and
0.7 % 2-mercaptoethanol. These cells were grown at 37°C
in an atmosphere which contained 95% air and 5% CO 2 .
MIN-6 cells were cryopreserved after reaching 
approximately 70% confluence using the same protocol 
which was used to store the HITm2.2 and RINm5f cell
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lines. MIN-6 cells were also preserved in a FCS: DMSO 
(9:1 v/v) mixture.
2.2.2: The growth and passage of the cell lines
The HIT-T15, HITm2.2 and RINm5f cell lines were rapidly 
defrosted by the addition of 2 ml of the appropriate 
growth medium to a cryotube. The contents of the cryotube 
were added to the appropriate culture medium to make up a 
final volume of 20ml. After this, the cells were 
centrifuged for 2 minutes at 1500 RPM in a bench 
centrifuge. The supernatant was then removed and the cell 
pellet was resuspended in an aliquot of medium. The cells 
were then vortexed gently and aliquoted into 9 cm tissue 
culture plates, before they were grown in 10 ml of the 
appropriate culture medium.
All of the three cell lines had their medium replaced 
after approximately 48 to 72 hours. After four to five 
days when the cultured cells reached confluence, they 
were re-seeded and then maintained at a lower cell 
density (HITm2.2 and RINm5f cells between 1: 5 and 1: 7 
and the HIT-T15 cells no more than 1: 3). The medium was 
discarded and the cells were then pre-washed with 10 ml 
of a sterile PBS buffer. After this buffer 
had been removed, 0.5 ml of a trypsin EDTA solution 
(0.25% v/v) was added at 37°C for approximately 1 minute 
(HIT-T15 cell line, a maximum of 5 minutes incubation
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with trypsin at 37°C). The cells were then passaged 
gently and resuspended in 20 ml of the appropriate growth 
medium. Following this the cells were centrifuged at 
1500 RPM for 5 minutes in a bench centrifuge. After 
centrifugation the cell supernatant was subsequently 
discarded and the remaining cell pellet was quickly 
resuspended in an appropriate volume of growth medium.
The cells were then mixed gently and reseeded into 
sterile tissue culture dishes (10 ml of medium per dish).
The MIN6 cell line was grown and maintained under 
slightly different conditions. These cells were initially 
defrosted at 37°C, with an appropriate volume of the DMEM 
growth medium. The cryotube contents were then added to 
20 ml of medium and centrifuged at 900 RPM for 5 minutes. 
The pellet was then resuspended in 5 ml of medium and the 
cells were grown in a 25 cmJ sterile flask for 24 hours.
MIN6 cells had their medium replaced every 
48 to 72 hours and they achieved confluence in one week. 
After this time period, they were subcultured and grown 
at a lower seeding density as described below. The medium 
was removed from the flask and the cells were washed 
twice with sterile PBS (2x 5ml washes). This wash buffer 
was discarded and 0.5 ml of a trypsin EDTA (0.25% v/v) 
solution was added to the cells. The flask was incubated 
at 37 °C for 3 minutes before being tapped gently to 
encourage cell detachment. This was followed by a 
resuspension of the cells in 10 ml of growth medium.
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During this time, care was taken not to produce a single 
cell suspension as it was reported that only aggregated 
cells would grow successfully.
The MIN-6 cell suspension was spun at 900 RPM for 
5 minutes. After this centrifugation, the supernatant was 
discarded and the cells were resuspended in 5 ml of 
medium. These cells were then seeded at a lower density
•3 "3
and were grown in 25 cmJ flasks (1:5 split) or 9 cm 
tissue culture dishes (1:2 split). The cell density was 
determined by using a standard graded haemocytometer and 
a trypan blue cell stain. Cells were then examined with a 
phase contrast microscope.
2.2.3: The preparation of ervthrocvte cell membranes
The preparation of erythrocyte cell membranes was 
performed essentially according to the protocol described 
by Gorga and Leinhard, (1981). To prepare the erythrocyte 
cell membranes, approximately 100 ml of human blood was 
divided between two 250 ml centrifuge tubes. These were 
equally balanced with PBS buffer. After centrifugation at 
4,500 RPM for three minutes the white cell layer and 
remaining supernatant were carefully removed. The tubes 
were then refilled and balanced with PBS and the cell 
pellet was then resuspended and centrifuged again.
The supernatant was removed and the remaining cells 
were divided into six 250 ml centrifuge tubes. Each tube
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was filled with ice cold haemolysing buffer and left on 
ice for around 20 minutes. Following centrifugation at
11,000 RPM for 20 minutes, the supernatant was removed 
and the cells were washed with the haemolysing buffer and 
centrifuged once again at 11,000 RPM for 20 minutes. This 
washing procedure was repeated three to five times until 
the supernatant was clear in appearance. The membranes 
were finally washed with 5 mM phosphate buffer and spun 
finally at 11,000 RPM for 20 minutes.
After this, both the supernatant and the cloudy 
membrane preparation were discarded. The red cell pellet 
which remained was solubilised in PBS and divided into 1 
ml aliquots. These membrane aliquots were stored at -70°C 
and a standard Lowry protein determination was performed 
(Lowry et a l .. 1951).
2.3: Sugar transport methods and uptake protocols
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The following transport methods were a modification of 
Eliam and Stein, (1974).
2.3.1: 2-deoxv-D-alucose and 3-0-methvl-D-qlucose 
transport into the HITm2.2 cell line. The effects of two 
standard transport inhibitors, cvtochalasin B and 
phloretin upon uptake into the HITm2.2 and RINm 5f cell 
lines.
All of the solutions and buffers were preincubated at 
37°C before the assay was started. The HITm2.2 and RINm5f 
cells (passage 10-20) were seeded at 0.15x 10^ cells per 
ml into six 4 well (1ml volume) tissue culture dishes.
After 48 to 72 hours the cells reached confluence at
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2x 10 cells per ml. The culture medium was then 
carefully removed by a gentle aspiration. The cells were 
washed with PBS (2ml per well) before the uptake of the 
sugar was assayed. Triplicate samples were analysed and 
each well was pre-treated for 2 minutes with 50 pi of 
inhibitor (20 pM final cytochalasin B and 100 pM final 
phloretin concentrations). This inhibitor was added 
carefully to cover the entire surface of the cells.
The assay was started by the addition of 50 pi of the 
radiolabelled sugar (either 2-deoxy-D-glucose or
3-0-methyl-D-glucose), at a final sugar concentration of 
50 pM (0.1pCi/ ml well). The sugars were incubated for
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varying time periods for the time course experiments. For 
time points of 10 seconds or less a metronome set at two 
beats per second was used. Transport was terminated by 
the addition of 3 ml of a 0.1 mM phloretin stopper 
solution which was added carefully down the side of the 
well. Care was taken not to disturb the cell monolayer. 
The solution was removed by gentle aspiration before a 
second phloretin wash was performed. After both washes, 
all the visible adhering droplets were removed and the 
wells were allowed to dry in air for 1 minute. Finally 
0.5 ml of a 0.1 M NaOH solution was added to each well to 
lyse the cells. The cell lysates were then aliquoted into 
scintillation vials (0.45 ml lysate: 5ml scintillant) for 
the CPM'S to be determined by a liquid scintillation 
counter. Zero-time counts were subtracted from all 
subsequent uptake values. These zero time values were 
estimated by addition of the radiolabelled sugar and 
phloretin solution simultaneously. Isotope equilibrium 
values were obtained by incubation of the cells for 
120 to 600 seconds with the radiolabelled sugar. Using 
the equilibrium value the fractional filling of the cells 
is calculated as follows:
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f = CPMt - CPM0
____________________  equation a
CPMi - CPM0
Here f is the fractional filling, CPM^ are the counts per 
minute at time t, CPM^ are counts per minute at isotope 
equilibrium and CPM0 are the counts per minute at zero 
time.
2.3.2: 6-deoxv-D-qlucose and D-fructose transport into 
the HITm2.2 and RINm5f cell lines
HITm2.2 and RINm5f cells (passage 15-25) were seeded at 
0.2x 10 cells per ml into 9 cm° tissue culture dishes. 
These cells reached confluence in 5 to 7 days. After this 
time period the cells were first detached from the dishes 
and the following uptake assay was performed on cells in 
suspension. The culture medium was removed and the cells 
were washed with PBS (10ml, 37° C) twice before being 
subjected to a gentle aspiration. Then 5 ml of a 
detachment buffer (1mM EDTA in PBS) was added for 
3 minutes at 37°C. After this time the cells were removed 
by gentle passage and the contents were then transferred 
to a universal tube. A standard cell count was performed 
before the cell suspension was spun at 1500 g for 
3 minutes in a bench centrifuge. The cell pellet was then 
resuspended in a HEPES (glucose free) buffer and respun
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to remove any residual EDTA. Following this the cells 
were then seeded at 10x 10 cells per ml. At this stage, 
and during the assay, it was important to periodically 
mix the cells to maintain an even suspension.
An appropriate number of assay tubes were then 
prepared. Each contained a final assay volume of 30pl. 
Each assay consisted of 5 pi of the competing sugar or 
buffer. The inhibitory sugar was diluted from a six times 
stock at a convenient concentration range. In addition to 
this 5 pi of radiolabelled 6-deoxy-D-glucose at 100uM 
final concentration (0.2pCi per tube) was also carefully 
pipetted to form a 10 pi droplet at the bottom of each 
tube (5pl 6-deoxy-D-glucose + 5pl inhibitory sugar or 
buffer). Transport at 22°C was initiated by addition of 
20 pi of suspended cells to each centrifuge tube. Here 
accurate pipetting was performed and care was taken to 
uniformly add the cells to the radiolabelled sugar 
precisely at the start of timing. For accurate 
manipulation no more than 3 tubes were processed at any 
one time.
Sugar uptake was stopped by the addition of 2 ml of a 
0.1 mM ice cold phloretin stopper solution. Each tube was 
then spun at 1500 g for 2 minutes in a bench centrifuge. 
The supernatant was then carefully removed by very gentle 
aspiration, which ensured that all of the adhering 
droplets which contained radiolabelled sugar were 
removed. This was followed by a second wash with the
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phloretin stopper solution. Each tube was dried to remove 
any radiolabelled buffer without disturbing the cell 
pellet. After all uptake estimations had been completed, 
the cell pellets were lysed by a resuspension in 0.5 ml 
of a 0.1 M sodium hydroxide solution. The cell 
lysates were incubated at 20°C for 30 minutes. These were 
then dispensed into scintillation vials 
(0.45ml lysate: 5ml scintillant) for the CPM'S to be 
determined by liquid scintillation.
Zero-time counts were subtracted from all subsequent 
uptake values. These were determined by addition of both 
radiolabelled sugar and the phloretin solution 
simultaneously. Isotope equilibrium values were obtained 
by incubation of cells for 60 to 120 seconds with 
labelled 6-deoxy-D-glucose. Using the equilibrium value 
the fractional filling of the cells was calculated as in 
equation a.
The inhibition data is analysed by a plot of vQ / v 
against the competing sugar concentration (I). Here vQ is 
the uninhibited rate of sugar entry, v is the inhibited 
rate and V is the osmotic volume (equation b-| ) . v is
_ -i
expressed in units of concentration sec and is 
calculated as follows:
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vQ = - 1 In (1-f).s0
_______________________  equation b
V t
equation b-|
V= Osmotic volume = 293 + Inside sugar concentration
293 + Outside sugar concentration
These equations assume that the backflux is non­
saturable. From equation b, f is the fractional filling, 
sQ is the initial substrate concentration outside and t 
is the incubation time in seconds. For single time point 
assays an incubation time of ten seconds was used to 
calculate the uptake rate. This represented a fractional 
filling of approximately 40%.
For the transport of D-fructose the same method was 
used as described in section 2.3.2.
2.3.3: 6-deoxv-D-qlucose. D-fructose and streptozotocin 
transport into the HIT-T15 and MIN-6 cell lines
This assay was modified from that described in section 
2.3.2. HIT-T15 and MIN6 cell lines were grown in 9 cm^ 
dishes until they reached confluence at around five days. 
The cells were reseeded (1:3 split) into 3 cmJ dishes and
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grown for four days before they reached confluence at 
3x 10^ cells per dish on the 5 ^  day.
Transport was performed in 3 cmJ tissue culture 
dishes. Before the assay was started the cells were 
washed twice with 3 ml of a calcium and magnesium free 
PBS. After each wash the PBS was removed by a gentle 
aspiration. Each assay was performed in triplicate using 
HEPES glucose free buffer. Sugar uptake commenced with 
the addition of 150 pi of a 100uM final concentration of 
6-deoxy-D-glucose (0.2pCi per dish). In addition to the 
6-deoxy-D-glucose, 75 pi of a competing sugar for the 
kinetic experiments or HEPES buffer was included for the 
time course experiments. For incubation times of less 
than 10 seconds a metronome set at two beats per second 
was used for timing purposes. Uptake was stopped by the 
addition of 3 ml of a 0.1 mM phloretin stopper solution. 
The phloretin solution was removed by careful aspiration 
and each dish was allowed to dry before the cells were 
washed again with a phloretin solution. Finally all the 
dishes were allowed to dry for 5 minutes. No more than 
three dishes were processed at any one time and each dish 
was removed from the 37°C incubation only when it was 
required. After all the uptake experiments were completed 
the cells were lysed by a resuspension in 1 ml of
0.1 M NaOH and allowed to stand for 30 minutes at 22°C. 
The lysates were then added to scintillation vials 
(0.95 ml lysate: 5 ml scintillant) for the CPM'S to be
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determined. The uptake of the sugar label was expressed 
as both a fractional filling and an initial velocity 
value as outlined in section 2.3.2.
Studies on the uptake of D-fructose were carried out 
using the same method as described in 2.3.2. In this 
case, a 100 pM final concentration of D-fructose 
(0.2pCi/ dish) was substituted for 6-deoxy-D-glucose. 
Similarly radiolabelled streptozotocin uptake and 
kinetics studies were performed as in 2.3.2. The 
modification here was that a 100 pM final concentration 
of streptozotocin (0.2pCi/ dish) was added to the cells 
in a final assay volume of 100 pi.
2.3.4: Investigation of streptozotocin toxicity in the 
HITm2.2 and RIN m5f cell lines
Essentially this method was a modification of that 
described in section 2.3.2. HITm2.2 and RINm5f cells were 
seeded at 0.15x 10^ cells per dish into 9 cm^ sterile 
culture dishes and were exposed to STZ. 6-deoxy-D-glucose 
transport assays were performed in suspension as outlined 
in section 2.3.2.
Experiments were also carried out with the 
phosphorylated analogue 2-deoxy-D-glucose. These studies 
performed on HITm2.2 cells, were an investigation upon 
the effect of the long term incubation of streptozotocin 
and its effect upon 2-deoxy-D-glucose transport. Here STZ
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was incubated at a final concentration of 5 mM 
for 48 hours. After this time the uptake of 
2-deoxy-D-glucose was assayed. HITm2.2 cells (passage 15)
f:
were seeded at 0.15x 10 cells per ml into 4 well tissue 
culture (1 cm^) dishes. The cells reached confluence in 
48 to 72 hours at 2x 10^ cells per dish. After 24 hours 
the growth medium was removed and the cells were washed 
three times with 3 ml of sterile PBS. A minimal glucose 
culture medium (containing glucose at 5 mM) was added to 
the cells. A final concentration of 5 mM STZ was added. 
This solution was sterile filtered from a convenient 
stock solution. Transport of 2-deoxy-D-glucose was 
performed as outlined in section 2.3.1. and the results 
were expressed as CPM against time.
An inhibition constant (K-[) for streptozotocin 
inhibition of 2-deoxy-D-glucose transport in the HITm2.2 
cell line was obtained. This method was essentially the 
same as described in 2.3.1 but various concentrations of 
STZ from 0 to 50 mM were substituted for phloretin and 
cytochalasin B.
64
2.4: An investigation of the binding of streptozotocin to 
the ervthrocvte cell membrane
2.4.1: The inhibition bv streptozotocin of cvtochalasin B 
binding to the ervthrocvte membrane
All of the buffers and the tubes were maintained at 4 °C
during the course of the experiment. At the start of the 
experiment the tubes were set up in duplicate with a 
total assay volume of 230 j j l I .  This included STZ at 
0, 1 , 2, 5, 10 and 20 mM. The assay also contained a 
radiolabelled cytochalasin B stock solution, which
included 2 mM cytochalasin E (final concentration) and a
1 mM final concentration of cytochalasin B (0.2pCi/ ul). 
Each time the difference in the final volume was made up 
by the addition of 5 mM phosphate buffer, adjusted to a 
final pH of 8.
The reaction was started by the addition of 180 y.1 of 
erythrocyte membranes (1mg/ ml) and the contents were 
then incubated at 4°C for three minutes. After this time 
period the tubes were spun in a refrigerated microfuge at
20,000 g for one minute. Then two 50 jjlI aliquots of the 
supernatant were counted in 8 ml of scintillation fluid.
A 10 y.1 aliquot of the cytochalasin B stock was also 
counted to obtain the total counts per minute. The 
inhibition of cytochalasin B binding by STZ was expressed
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as free cytochalasin B / bound, against the free STZ 
(inhibitor) concentration.
A plot which analysed the streptozotocin inhibition 
of the cytochalasin B binding to the erythrocyte cell 
membrane was also performed according to the following 
protocol.
Here a series of tubes were set up in duplicate with 
an appropriate range of cytochalasin B concentrations 
with and without a final concentration of 4 mM STZ. A 
dual labelled stock which contained a 2 mM final 
concentration of cytochalasin B (0.2pCi/ pi) and 
radiolabelled sucrose (0.2pCi/ pi), were added to each 
tube. The total assay volume of 40 pi was adjusted 
accordingly with a 5 mM phosphate buffer adjusted to a 
final pH 8.
A 180 pi aliquot of a 1mg/ ml membrane suspension was 
added to each tube, mixed and allowed to stand at 4°C for 
three minutes. Each tube was then spun at 20,000 g for 
one minute. Then, two 25 pi aliquots of the supernatant 
were counted in 8 ml of scintillation fluid. Two vials 
which contained the 20 pi aliquots of the dual labelled 
stock were also counted. The latter gave the total 
separate H) and 0 ^  C) CPM's. The results were 
expressed in a graphical format outlined in chapter 3.
All of the protein concentrations were determined by 
using the Lowry method (Lowry et a l .. 1951).
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2.4.2: An investigation of the reversibility or 
irreversibility of streptozotocin inhibition of 
cvtochalasin B binding
A series of tubes were set up and incubated at 37°C for a 
range of time points (30 minutes to 18 hours). One series 
of tubes contained a final concentration of 10 mM STZ 
while the other contained OmM STZ. In this assay each 
tube contained a final concentration of erythrocyte ghost 
membranes at 1 mg per ml suspended in PBS 
buffer. The final assay volume was 210 pi and the pH was 
adjusted to 8.
Following the incubation with membranes each tube was 
spun at 20,000 g for one minute in a refridgerated 
microfuge. The supernatant was then removed and the 
membranes were resuspended in a 210 pi volume of 
phosphate buffer (pH 8). Following this, 10 pi of a 1 mM 
final cytochalasin B solution was added to a tube which 
contained no inhibitor. This control tube was incubated 
for a zero time period.
A 10 pi aliquot of a radiolabelled cytochalasin B 
stock (0.2pCi/ tube) which contained final concentrations 
of 2 mM cytochalasin E and 1 mM cytochalasin B, was added 
to each tube. The tubes were then incubated on ice at 4°C 
for 3 minutes. Each tube was spun in a refrigerated 
microfuge for 1 minute at 20,000 g. Then two 50 pi 
aliquots of each supernatant were counted in 8 ml of
scintillation fluid. A 10 jjlI aliquot of the stock 
cytochalasin B label was taken for a total CPM 
determination. A standard protein determination was also 
performed (Lowry et a l .. 1951).
2.5: The synthesis of radiolabelled streptozotocin
2.5.1: The chemical synthesis of labelled streptozotocin
The synthesis of labelled streptozotocin 
((^-C) 2-deoxy-2-( { [methylnitrosoamino) carbonyl} 
amino]-D-glucopyranose) consists of two main stages 
illustrated in the following scheme:
(1 ) = D-Glucosamine hydrochloride
(2) = 2-(3-Methylureido)-2-deoxyglucopyranose (GU)





(1) (2) (3) CH;
The synthesis of STZ was based upon a modified method of 
Kawada (et a l ., 1986). It was not clear from the 
communication whether these authors used commercial
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N-methylisocyanate (MIC) for the synthesis. From 
enquiries made to a number of chemical companies MIC 
synthesis had been discontinued for the following 
reasons. It was unstable during transport, toxic when 
produced on a relatively large scale and also it was not 
commercially viable. The purity and stability of MIC was 
important for the formation of the final STZ yield. MIC 
synthesis was performed with many modifications on two 
main protocols which are outlined below: (In both cases 
MIC was synthesized initially on a small scale and scaled 
up when the optimum conditions had been established).
1. The synthesis of N-methylisocyanate from triphosgene 
and N-methylamine.
2. The synthesis of N-methylisocyanate from the 
distillation of dichlorodiphenylsilane and sodium azide.
Details of both methods chosen for the synthesis are as 
follows. Method 2 was the most successful protocol in 
terms of the final MIC yield. This method was a 
distillation process with a well defined endpoint. A 
measurable quantity of MIC was produced using this 
method. Method 1 relied on a chemical transformation 
where a molecule of phosgene would react with 
N-methylamine to produce MIC.
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2.5.2: The distillation of N-methvlisocvanate
A two part reaction scheme for the distillation is shown 
below:
Part 1.








The distillation of N-methylisocyanate was carried out as 
described in a translation of a method outlined by 
Kricheldorf, (1972). The MIC was synthesized on a number 
of occasions. It was found that a suitable yield was 
achieved using a 12 mmole (1/50^) scale. Then a further 
full scale synthesis was performed. The final yield at 
this reduced scale was approximately 20% (250jjl1 , 0.24g),
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with the amount being increased upon scaling up the 
distillation.
Dichlorodiphenylsilane (146g, 0.6 moles) was stirred 
with 1.3 moles of sodium azide in 500 ml of dry quinoline 
for 10 hours at 120°C. Before the addition of the 
anhydride the quinoline was heated to 100°C to remove any 
excess water which may have accumulated. Then, the flask 
was allowed to cool to 22°C. 1 mole of acetic anhydride 
was added to the cooled solution which reacted 
exothermically. The mixture was then heated by oil 
immersion until nitrogen gas was produced at 70°C. The 
reaction was controlled by regulation of the temperature 
so that it continued to its end in approximately 
30 minutes. The temperature was only allowed to exceed 
100°C for a short time period at the very end of the 
reaction.
The isocyanate was distilled off through a modified 
angular distillation head and collected in a flask. The 
anhydride was converted into the isocyanate with a 
reported 95 % approximate yield (Kricheldorf, 1972) and 
therefore the end product yield was dependent on both the 
distillation and the batch size. Initially the 
N-methylisocyanate was distilled on a small scale and to 
ensure a maximum purity the acetic anhydride was 
redistilled on every occasion. The best yield of MIC 
which was obtained was 40% (25 ml, 24 g). This 
distillation was then performed on a number of occasions
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to obtain a sufficient quantity of the MIC. The MIC was 
stored in a desiccator (in the dark) for no more 
than 24 hours.
Some important factors which were crucial to the 
production of distilled MIC as the actual yield was only 
40% are outlined below. It was important to immerse the 
reaction vessel at the correct angle in the oil bath.
This encouraged a suitable flow rate of MIC which was 
finally collected. Other important components were the 
reflux time of the dichlorodiphenylsilane with the sodium 
azide. Although the recommended time was 10 hours, it was 
found that an increased reflux time of up to 18 hours or 
even longer increased the yield of the end product. The 
Claisen distillation head was constructed with a large- 
diameter which was reduced towards the condenser. Such 
alterations minimised the amount of MIC which was lost 
between the top of the condenser and the collecting 
vessel.
2.5.3: The synthesis of N-methvlisocvanate from
triphosgene
The alternative method for the synthesis of 
N-methylisocyanate which was investigated was based on 
triphosgene. This was provided by Aldrich International. 
This method was closely coupled to the formation of STZ 
during the initial attempts with this method. The 
reaction for the formation of the MIC is described below
Methylamine + Triphosgene
Solvent
MIC + Hydrochloric acid + Carbonyl chloride
The synthesis of the N-methylisocyanate was carried out 
using the following method. 0.12 mmol of methylamine 
(8.1 mg) was dissolved in 20 pi of solvent 
(2 mmol solvent: 1 mmol methylamine), before 0.04 mmol 
(12 mg) of triphosgene was added. The reaction then 
proceeded through to completion with some modifications.
Several procedures for the synthesis of 
N-methylisocyanate were attempted as outlined in the 
following reaction schemes. These summarised the main 
conditions and reagents that were used. At first the MIC 
was synthesized separately. The appropriate solvent
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systems for both the methylamine and the triphosgene are 
shown in a flow chart format. These trials were performed 
at 4°C and at -10°C using non radiolabelled glucosamine. 
Following the most successful method the yield of MIC was 
determined by using an aliquot of radiolabelled 
glucosamine (1]iCi). This was achieved by its addition at 
the start of the reaction. The reaction was allowed to 
proceed through to the urea stage. The formation of the 
urea was determined by thin layer chromatography, which 
exploited two types of solvent system. A quantitative 
estimation of the formation of GU was determined by the 
division of a tic plate into ten equal portions. Each 
section of the plate was then counted in 5 ml of 
scintillant by liquid scintillation (Packard counter). 






performed at 4 and -10°C
N-methylisocyanate + Glucosamine hydrochloride 

















4 and -10°C 
N-methylisocyanate
Y
D) Methylamine + Triphosgene
Acetonitrile y added portion wise
4 and -10°C 
N-methylisocyanate
E) Methylamine + Triphosgene
Aqueous y Dichloromethane
Glucosamine free base 
N-methylisocyanate
Several problems were encountered with methods A) to D). 
When these methods were performed, no product could be 
readily identified or purified. This is discussed further 
in chapter 4. Method E was the most successful method and
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is described in detail below. In all of the above flow 
charts the MIC was synthesized separately at first before 
it was added to the glucosamine. In method E the 
glucosamine free base was included together with the 
other reagents.
2.5.4: The synthesis of radiolabelled 2-(3-methvlureido)- 
2-deoxv-D-qlucopvranose (GU) using the triphosgene method
The synthesis of GU is described below. 1OOpl of 
D-glucosamine hydrochloride (0.1 mmol, 20 mg) and 
radiolabelled D-glucosamine (1pCi/ 0.1 mmol) were passed 
through an Amberlite OH- resin (IRA 93, std. grade) 
exchange column. This column contained 400mg of the 
cationic resin. The column was washed again with 1OOul of 
distilled water. A total of 200 pi of the glucosamine 
free base eluant was collected and concentrated to a 
minimum volume.
The free base was then stirred in a quick fit flask 
at 4°C. 0.12 m moles of triphosgene ( 35 mg, 50 pi) 
solubilised in dichloromethane was added portionwise to 
the mixture. Then aqueous N-methylamine 
(8.1 mg, 0.12 moles) was added dropwise and the whole 
solution was stirred at 4°C for approximately two hours.
The solvents were then removed under nitrogen. 
Formation of the GU was assessed by thin layer 
chromatography (tic) on preformed plates. The solvent
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system was Acetonitrile: Acetic acid: Ethanol: water 
(13:1:2:4) which was finally changed to
Ethyl acetate: Methanol: water (5:2:1). It was found that 
a better separation of the endproduct was achieved with 
the latter system. This latter solvent system was 
retained for all of the subsequent experiments.
The residual solution was dissolved in 130 pi of 
1 M acetic acid before 0.12 mmol of sodium nitrite 
( 8.5 mg) was added portion wise at 4°C over a 30 minute 
period. After this time 26 pi of 10% (1M) hydrochloric 
acid was added dropwise and the whole mixture was stirred 
at 4°C for approximately 1 hour. At this stage the 
formation of the final product was assessed by 
neutralising 5 pi of the endproduct with Amberlite 
monobed resin MB1 (analytical grade). This synthesized 
product was set against commercial STZ (Relative front 
(Rf) of approximately 0.2) using the appropriate solvent 
system. The reaction mixture was saturated with 5ml of a 
saturated ammonium sulphate solution (pre warmed at 37°C) 
and extracted with two 9ml portions of ethyl acetate: 
tetrahydrofuran (1: 8).
The organic layer was then dried over magnesium sulphate 
and concentrated by rotary evaporation. A 50 pi aliquot 
was analysed by tic. The tic plate was sectioned into ten 
equal parts and counted in a liquid scintillation counter 
(1 tic plate portion: 5 ml scintillant). The final yield 
was calculated at approximately 10 % (2 mg, 0.1pCi).
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2.5.5: The synthesis of radiolabelled streptozotocin from 
distilled N-methvlisocvanate
To optimise the reaction conditions to ensure a maximum 
yield of labelled STZ, the synthesis of GU was performed 
on a small non-labelled scale. This was followed 
by the synthesis of radiolabelled STZ. The full 
scale synthesis of radiolabelled STZ was performed twice 
(48y.Ci in total; 24pCi per synthesis) according to the 
modified method of Kawada (et a l ., 1986).
Several procedures for the synthesis of GU were 
carried out as indicated by the reaction schemes below. 
Each time the formation of GU was illustrated by its 
distribution upon a tic plate. The solvent system was 
Ethyl acetate: Methanol: water (5: 2: 1).
A ) , B) and C)
Glucosamine + N-methylisocyanate






D ) , E) and F)
N-methylisocyanate 
Time
D) 1/2 to 1 hours 22°C
E) 2 to 4 hours/ 4°C
F) 4 hours plus/ -10°C
2-deoxy-D-glucopyranose
Overall method E was determined to be the most 
successful. This was assessed by qualitative tic. The tic 
plates were charred with concentrated sulphuric acid and 
an Rf value of 0.55 was calculated for the end product. 
After 4 hours or longer the GU was seen to decompose, - 
whereas up to 2 hours some of the glucosamine still 
remained.
Several procedures were also carried out on the GU 
leading to the synthesis of STZ. These procedures are 
indicated in the following reaction schemes. Common parts 
of the reaction schemes have been combined centrally for 
simplification. From the first scheme below, both of the 
methods A) and B) have an ammonium sulphate saturation 






A) B) Glucosamine Urea
A) 1M Acetic acid 
4°C portion wise addition 
30 minutes stirring 
10% Hydrochloric acid 
dropwise addition o
4°C 1 hour stir
B) 1M Acetic acid 
22°C one amount 
15 minutes stirring 
10% Hydrochloric acid 
one addition 
22°C 1 hr. stir
A) B) Ammonium Sulphate saturation
twice extracted with
Ethyl acetate: Tetrahydrofuran (THF) 
(1: 8)
o





Purified by silica gel chromatography 
Ethyl acetate: Methanol: Water, 7: 2:1
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C) D) Glucosamine Urea
C) Acetic acid 
-10°C portion wise 
30 minutes stir
D) Acetic acid 
4°C portion wise 
1 hour stir
Hydrochloric acid 
dropwise 10°C for 1 hour
Hydrochloric acid 
O  -c 4°C for 1 hour
Streptozotocin
♦
Final product separated on silica
gel (G 200) column
The preferred method was estimated to be D. The two 
methods D and E were combined and are outlined below.
D-Glucosamine hydrochloride (0.025 mmol/ 5 mg) and 
radiolabelled D-glucosamine hydrochloride 
(24 pCi per synthesis) were both solubilised in 2 ml of 
distilled water. This solution was then passed through an 
Amberlite OH- resin (IRA 93 standard grade,
0.7 g resin/ mmol glucosamine hydrochloride) column which 
contained 100 mg of cationic resin. Subsequently, 2 ml of 
the glucosamine free base mix was eluted through the 
column which was followed by a second 2 ml wash with 
distilled water. The total elutant was collected and 
concentrated to a final minimum volume of 100 u l .
Figure 2.1: Elution profile calculated from fraction 
aliquots (50pl) of the final product in the synthesis of 
D-streptozotocin. The fractions corresponding to the 
large peak were pooled, concentrated and aliquoted. The 
product was D-1-^C-streptozotocin. The solvent system 
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N-methylisocyanate (I0mg/10 pl/0.17 mmol) was added 
to the glucosamine free base at 4°C under stirring for a 
time period of 2 to 3 hours. After this, the formation of 
the urea derivative was verified by thin layer 
chromatography on pre-prepared (Merck) silica gel G 200 
plates (solvent system, ethyl acetate : methanol : water; 
5 : 2 : 1 ) .
The urea was then dissolved in 33 pi of a 1M (15 %) 
acetic acid solution and 25 pi of an 80 mg/ ml 
(0.03 mmol) sodium nitrite stock was added portion wise 
at 4°C over a 30 minute period.
Finally, 6.5 pi of a 1 M hydrochloric acid solution 
was added dropwise and the whole mixture was stirred for 
1 hour at 4°C. This produced the end product 
( 60% yield, 3 mg) after separation on a silica gel G 200 
column with the appropriate ethyl acetate : methanol : 
water (5 : 2 : 1 v/v) solvent system. The progress of STZ 
formation was assessed by neutralising a small portion of 
the endproduct with Amberlite monobed resin 
(MB1 analytical grade, 1 ml of 1 M HCL to 0.7 g of the 
resin). The final product was then run against commercial 
STZ which was the highest grade available.
The product was applied to a silica gel G 200 column 
and the appropriate number of fractions were collected 
(50x 1 ml). An aliquot of each fraction was analysed to 
determine the position of product elution. From figure 
2.1 fractions 4 to 10 were concentrated, freeze dried and
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stored at -20°C (7x 4pCi aliquots). The final combined 
yield of radio-labelled STZ from two experiments 
approximated to 28)iCi (58%).
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CHAPTER 3 RESULTS OF A CHARACTERISATION OF THE HEXOSE 
TRANSPORT PROPERTIES OF FOUR PANCREATIC BETA CELL LINES
All of the following graphical plots in chapter 3 are 
representative examples of two or more experiments. The 
estimation of the experimental error of each data point 
has been determined by calculating the mean and standard 
deviation of triplicate points. Estimations of 
experimental error for the kinetic and transport data are 
expressed as the standard error. Where these are given 
the standard error was calculated from the regression of 
values obtained in three or more experiments.
3.1: Sugar transport into the HITm2.2 cell line
3.1.1: The transport of 2-deoxv-D-qlucose and 3-0-methvl- 
D—glucose and the effect of two transport inhibitors 
phloretin and cytochalasin B on sugar uptake
The phosphorylated glucose analogue 2-deoxy-D-glucose and 
the non-metabolised analogue 3-0-methyl-D-glucose were 
both used in separate experiments with the HITm2.2 cell 
line to perform some initial transport studies. These 
early assays were performed with HIT cells still attached 
to the tissue culture dish surface. HITm2.2 cells were 
initially used to optimise the assay because it was found 
that at a low passage number they formed a stable
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monolayer. This provided a stable transport assay system 
to begin to characterise sugar uptake into 
these cells. A time course experiment performed with
3-0-methyl-D-glucose (figure 3.1). The result from this 
experiment indicated that the sugar was transported and 
equilibrated rapidly within 2 minutes. The fractional 
filling at 50% or f= 0.5 (t 1 /2 )/ was 21 . 7jfseconds. This 
contrasted with similar results obtained with
2-deoxy-D-glucose (t -| / 2= 220.4 seconds). With the latter 
full equilibration is not attained as the
2-deoxy-D-glucose is phosphorylated once it is trapped 
inside the cell (figure 3.2). 2-deoxy-D-glucose is 
phosphorylated and metabolized by its incorporation into 
the glycolytic pathway. This phosphorylation prevents-the 
equilibration of 2-deoxy-D-glucose when compared with 
non-metabolized 3-0-methyl-D-glucose.
The advantages of studying sugar transport into cells 
which are attached to an immobilised surface, preferably 
as a monolayer, compared to a suspension will be 
outlined. It was found that a study of sugar uptake was 
limited when the HITm2.2 and RINm5f cells were attached 
to a suitable surface. The detachment of RIN and HIT 
cells was reported to reduce the viability 
(Atkins unpublished communication), so initially it was 
seen to be an advantage to assay immobilised cells. The 
problems experienced with transport assays which were 
performed on immobilised cells, led to the development of
Figure 3.1: A time course for the uptake of 1OOpM 3-0- 
methyl-D-glucose at 20°C in the HITm2.2 cell line, 
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Figure 3.2: Time course for the uptake of 1 OOjjlM 2-deoxy- 
D-glucose at 20°C in the HITm2.2 cell line.
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a suspension assay. This enabled a more detailed kinetic 
analysis to be performed with 6-deoxy-D-glucose. The 
problems experienced with the immobilised cell assay, 
together with the adjustments made to this assay are 
outlined below:
1. The cells were observed to detach very easily from 
the culture dish upon addition of the assay buffer. This 
prevented the accurate determination of the cell protein 
between different experimental samples.
2. The final quantity of radiolabelled sugar was 
increased approximately ten fold. This however, did not 
compensate for the low CPM's obtained when the sugar 
attained isotope equilibrium.
3. For sugar uptake to be estimated the assay volume 
was decreased. From the results this volume reduction was 
observed to increase the CPM's obtained when the sugar 
attained equilibrium. This volume reduction also resulted 
in the cells drying out over longer incubation times.
4. Sugar transport was measured at 37°C. It was 
difficult to maintain this temperature accurately for the 
duration of the experiment. As a result of the 
temperature fluctuations all subsequent transport 
experiments were performed at 22°C.
A series of uptake experiments in HITm2.2 cells were 
performed with 2-deoxy-D-glucose and
3-0-methyl-D-glucose. From these preliminary studies,
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sugar transport was shown to be inhibited by two standard 
sugar transport inhibitors. These were phloretin and 
cytochalasin B. These early experiments were performed 
using an immobilised cell assay. This should therefore be 
accounted for when interpreting the data from these 
experiments. Figure 3.3 illustrates the result of 
cytochalasin B inhibition on the transport of
3-0-methyl-D-glucose into the HIT m2.2 cell line. Sugar 
transport in the presence of cytochalasin B is reduced 
approximately 1.25 fold, when compared with a suitable 
control. Similarly 2-deoxy-D-glucose uptake in the 
presence of 100 pM phloretin (figure 3.4) is also 
illustrated. After a time interval of 10 minutes
2-deoxy-D-glucose uptake in the presence of phloretin is 
3.5 fold lower than the appropriate control experiment.
3-0-methyl-D-glucose uptake in the presence of 100 pM 
phloretin (figure 3.5) is also reduced to around two fold 
lower than the control at an equilibrium time of
1 minute. The CPM'S s obtained with 3-0-methyl-D-glucose 
decreased fractionally after isotope equilibrium had been 
reached (between 30 and 90 seconds). This observed CPM 
decrease is due to a back flux of the non-metabolised 
label, from the inside to the outside of the cell. This 
contrasted with the transport of 2-deoxy-D-glucose. As 
this sugar is metabolized it is immediately 
phosphorylated once it enters the cell. The attachment of
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the phosphate group to 2-deoxy-D-glucose prevents its 
backflux or exit from the cell.
3.1.2: The calculations for the kinetic analysis of 6- 
deoxv—D-qlucose transport
Non-metabolised 6-deoxy-D-glucose which is not easy to 
obtain commercially, was used for a series of transport 
experiments. The initial transport studies were performed 
to optimise the assay. Results from preliminary time 
course experiments indicated that 6-deoxy-D-glucose was 
transported, but the assay procedure required some 
modifications.
Preliminary time course experiments indicated that 
6-deoxy-D-glucose reached isotope equilibrium faster than 
metabolized 2-Deoxy-D-glucose. It was apparent that 
70 volumes of the ice cold HEPES buffer, with the 
inclusion of phloretin at a O.ImM final concentration, 
was an effective stopping agent. The following final 
modifications were made in adjusting the 
6-deoxy-D-glucose assay:
1. A reduction in assay volume from 100 to 30 pi.
2. An increase in the cell number from 2 x 10 to
7
10x10 cells per assay.
3. A greater amount of labelled 6-deoxy-D-glucose was 
included to increase the CPM's attained at isotope 
equilibrium.
84. A decrease in the assay incubation times when 
estimating the initial rates of sugar uptake was required 
because of the high rate of hexose transport.
5. A reduction of the assay temperature 
from 37°C to 22°C
Calculations for both the fractional filling and the 
velocity for the uptake of 6-deoxy-D-glucose are defined 
in equations a and b (chapter 2). The various equilibrium 
values were obtained by the incubation of the cultured 
cells for 60 to 120 seconds with radiolabelled 
6-deoxy-D-glucose. Using this value, the fractional 
filling f was thus calculated as from equation a.
For the single time point assays used in the inhibition 
studies, an incubation time of 10 to 15 seconds was used. 
This incubation time represented a fractional filling of 
approximately 40% for the assays overall.
In calculating the uptake of 6-deoxy-D-glucose a 
simplified form of the Eliam and Stein (1974) equation 
was used. This equation defines the net entry of the 
sugar label into the cell and is illustrated in equation 
b. To determine the Michaelis Menten (Km ) constant and 
the maximal velocity (Vmax) values, a s/v against s plot 
was plotted for both 6-deoxy-D-glucose and D-fructose.
The Inhibition constants (Ki s) were calculated from the 
following equation (Holman et a l ., 1981):
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v 0  = 1  + 1
___________   equation c
v Ki
From the above equation v is the inhibited rate of sugar 
transport, vQ the uninhibited rate and I is the inhibitor 
concentration.
3.1.3: 6-deoxv-D-qlucose transport and its inhibition bv 
D-qlucose analogues
For the estimation of the inhibition constants of the D- 
glucose analogues, the technique has tended to over 
estimate the final K-[. This applies to both 6-deoxy-D- 
glucose and the D-fructose experiments.
To establish the nature and specificity of the 
transporter in the HITm2.2 cell line, a series of 
experiments with non-metabolised 6-Deoxy-D-glucose were 
performed. These experiments also included both 
6-deoxy-D-glucose uptake and Km determinations. The 
results of a time course (Figure 3.6) for 
6-deoxy-D-glucose uptake at 20°C, demonstrated that this 
analogue was transported with a 50% fractional filling 
(t t /2) °f 17.3 ± 1.4 seconds. The equilibration of 
6-deoxy-D-glucose was reached in 1 minute. Transport 
specificity was investigated by using a series of 
analogue inhibitors of 6-deoxy-D-glucose transport. The
Figure 3.7: A Hanes plot of the uptake of 6-deoxy-D- 
glucose, using a 12 second single time point assay at 
20°C in the HITm2.2 cell line.
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Figure 3.8: Inhibition of 100pM 6-deoxy-D-glucose uptake 
by D-glucose,in the HITm2.2 cell line.
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Figure 3.9: Inhibition of 100]iM 6-deoxy-D-glucose uptake
by D-fructose, in the HITm2.2 cell line.









Figure 3.10: Inhibition of 100pM 6-deoxy-D-glucose uptake 
by D-mannose, in the HITm2.2 cell line.
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aim was to obtain a series of inhibition constants (K^'s) 
for a range of analogues at each hexose carbon position. 
From these experiments, both the spatial and hydrogen 
bonding requirements of the transporter binding site 
could be determined. The inhibition constants were 
calculated by using a range of sugar inhibitor 
concentrations at a fixed 100 pM 6-deoxy-D-glucose 
concentration. The results were subsequently plotted on a 
Hanes plot and fitted by linear regression.
Initially it was investigated whether preincubation 
with the inhibitor or the simultaneous addition of the 
inhibitor and 6-deoxy-D-glucose would be the most 
appropriate for the assay procedure. It was found to be 
more convenient to add the detached cells (small volume) 
to the inhibitor and the 6-deoxy-D-glucose tracer 
(large volume) for the purpose of assay accuracy and 
repeatability. A Hanes plot for the uptake of 
6-deoxy-D-glucose is shown in figure 3.7.
From these results a Km = 2.10 ± 0.40 mM and a
_ i
vmax = 0-21 ± 0.03 mM sec have been determined.
The potential substrate's D-glucose, D-fructose, 
D-mannose and D-galactose were used as sugar inhibitors 
of 6-deoxy-D-glucose transport. Figures 3.8, 3.9, 3.10 
and 3.11 illustrate results from which inhibition 
constants were calculated to be: 2.0 ± 0.6 mM for 
D-glucose, 228.3 ± 84.6mM for D-fructose, 9.0 ± 2.4mM for 
D-mannose and 21.0 ± 4.2 for D-galactose. Conclusions
Figure 3.11: Inhibition of lOOpM 6-deoxy-D-glucose uptake
by D-galactose, in the HITm2.2 cell line.






0 10 20 30 40 50
I (mM)
Figure 3.12: Inhibition of 1 OOjiM 6-deoxy-D-glucose uptake 
by 2-deoxy-D-glucose, in the HITm2.2 cell line.
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from these results indicate that the natural substrate 
D-glucose, has the expected highest affinity for the 
transporter binding site. D-fructose has the lowest 
affinity for the transporter binding site, followed by 
D-galactose and finally D-mannose.
Inhibition by carbon-1 analogues
There were no suitable glucose derivatives available to 
study the one position on the hexose ring.
Inhibition by carbon-2 analogues
The specificity study at the carbon-2 position used the 
available analogues, 2-deoxy-D-glucose and 
2-deoxy-D-galactose as potential inhibitors of 
6-deoxy-D-glucose uptake.
The Ki values obtained were 6.3 ± 1.8mM for 
2-deoxy-D-glucose and 43.2 ± 17.6mM for
2-deoxy-D-galactose as shown in figures 3.12 and 3.13. 
The carbon-2 epimer D-mannose (figure 3.10) was found to 
inhibit with a Ki of 9.0 ± 2.4mM.
Inhibition by carbon-3 analogues
The carbon 3 position was analysed using the
3-0-methyl-D-glucose analogue. From figure 3.14 the 
inhibition constant obtained was 10.0 ±0.2 mM. The
3 positional hydroxyl group appears to demonstrate a 
moderate binding affinity for the transport site.
Figure 3.13: Inhibition of 100pM 6-deoxy-D-glucose uptake
by 2-deoxy-D-galactose, in the HITm2.2 cell line.
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Figure 3.14: Inhibition of 100pM 6-deoxy-D-glucose uptake 
by 3-0-methylglucose, in the HITm2.2 cell line.
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Inhibition by carbon-4 analogues
As deoxy analogues were unavailable for this study,
4.6-0-ethylidene-D- glucose was used as the only 
inhibitor of 6-deoxy-D-glucose transport. The value 
obtained was 100.0 ±3.8mM (figure 3.15). It can be
inferred from this inhibition study that
4.6-0-ethylidene-D-glucose demonstrates a partial 
inhibition of 6-deoxy-D-glucose uptake.
Inhibition by carbon-5 analogues
There were no deoxy or thio glucose derivatives available
to study the five positional oxygen.
Inhibition by carbon-6 analogues
The analogues used to study the six position hydroxyl 
were 6-deoxy-D-glucose and 6-deoxy-D-galactose. From 
figure 3.7 the Km for 6-deoxy-D-glucose was calculated to 
be 12.0 ± 2.3 mM. 6-deoxy-D-galactose has no detectable 
affinity for the glucose transporter in this particular 
cell line. Therefore no was determined. The fungal 
inhibitor cytochalasin B, from figure 3.16 will inhibit 
6-deoxy-D-glucose transport with a K ^ =  1.65 ± 0.01 jjlM .  
Therefore this compound binds with a high affinity to the 
transporter. Table 3.1 outlines the results of all of the 
inhibition studies on the uptake of 6-deoxy-D-glucose. 
This table represents the complete specificity analysis 
as allowed by the availability of analogues for use as
Figure 3.15: Inhibition of 1 OOpM 6-deoxy-D-glucose uptake
by 4,6-0-ethylidene-D-glucose, in the HITm2.2 cell line.
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Figure 3.16: Inhibition of 1OOpM 6-deoxy-D—glucose uptake 
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inhibitors. A calculation of the intracellular water 
space for 6-deoxy-D-glucose in the HITm2.2 cell line was 
performed. This calculation was determined from a time 
course of the uptake of 6-deoxy-D-glucose. Inferences 
from the experimental results indicated that the sugar 
uptake was fairly rapid. The 50% fractional filling was 
determined to be 12 seconds and an equilibrium was 
reached and maintained in one minute.
Using the number of CPM'S retained inside the cell at 
equilibrium and the specific radioactivity of the 
substrate, the intracellular volume accessible to the
o
analogue was calculated to be 0.96 pi per 10° cells.
The use of a non transported labelled marker to 
determine the proportion of CPM'S in the extra cellular 
space of the pellet was not considered necessary. As the 
CPM'S in the time zero determinations were low. This was 
due to the large volume of the stopper solution which was 
used to wash the cells.
3.1.4 : D-fructose transport and its inhibition bv 6- 
deoxv-D-qlucose
Radiolabelled D-fructose experiments were performed in 
accordance to the 6-deoxy-D-glucose protocol. In contrast 
to the erythrocyte type, the islet and liver type 
transporters are reported to transport fructose 
(Gould et_al., 1991). A time course for the uptake of
Figure 3.17: Time course for the uptake of 1OOpM D-
fructose versus time at 20°C, in the HITm2.2 cell line.
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Figure 3.18: A Hanes plot of D-fructose uptake using a 12 
second single time point assay at 20°C, in the HITm2.2 
cell line.
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1 0 . 0  ± 0 . 2
100.0 ± 3.8 
N.D.I.
Fungal inhibitor Cytochalasin B 1 . 65± 0.01 )jlM
Table 3.1: A table illustrating the results of an 
inhibition study which was performed on the HITm2.2 cell 
line. A range of D-glucose analogues were used to 
determine their ability to compete with 6-deoxy-D- 
glucose. N.D.I. = No Detectable Inhibition.
94
D-fructose was performed. Figure 3.17 shows a graphical 
plot from which a 50% fractional filling (t-| /2) °f
15.8 ± 1.4 seconds was calculated. The equilibrium was 
reached and maintained in around 60 seconds. Kinetic data 
for D-fructose transport was calculated from figure 3.18. 
This data included a Km = 2.58 ± 0.20mM and a 
Vmax = 0.047 ± 0.02mMs-  ^ for D-fructose.
From inhibition studies in the HITm2.2 cell line, 
D-fructose is known to inhibit the uptake of the 
6-deoxy-D-glucose analogue weakly. This K^ was determined 
to be 228.3 ± 84.6 mM (figure 3.9). Conversely, 
6-deoxy-D-glucose will also inhibit the uptake of 
1OOpM D-fructose (figure 3.19) with a calculated 
Ki of 52.0 mM. From these results it can be inferred that 
both of these labels are taken up by the same transporter 
type.
3.2 Sugar transport into the RINm5f cell line 
3.2.1: 6-deoxv-D-qlucose transport and
3-0-methvl-D-qlucose uptake in the presence of phloretin
The uptake of 3-0-methyl-D-glucose into the RINm5f cell 
line in the presence of 100)jlM phloretin is shown in 
figure 3.20. Here transport under phloretin is reduced to 
around 1.5 fold at equilibrium.
Figure 3.19: The inhibition of 100pM D-fructose uptake by
the 6-deoxy-D-glucose analogue, in the HITm2.2 cell line.
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Figure 3.20: The inhibition of the uptake of 50 jjlM  3-0- 
methylglucose (black triangles) in the RINm5f cell line. 
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The RINm5f cell line was analysed the same way 
as the HITm2.2 cell line. A time course for the 
uptake of 6-deoxy-D-glucose was calculated and plotted 
(figure 3.21). From figure 3.21 a t-j/2 of 
10 ± 0.7 seconds was determined. The sugar was 
equilibrated after about 90 seconds and maintained for up 
to 3 minutes. Figure 3.22 illustrates results of a Hanes 
plot for 6-deoxy-D-glucose. The Km and Vmax values were 
calculated to be 3.62 ± 0.98 mM and 0.43 ± 0.09 mMs- ^ .
The assay was developed as for the HITm2.2 cell line and 
a series of specificity studies were performed with 
various analogue inhibitors. From these studies 
inhibition constants (Ki's) were calculated.
3.2.2: The inhibition of 6-deoxv-D-qlucose transport bv 
D-alucose analogues
D-glucose, D-mannose, D-fructose and D-galactose were 
used as possible substrate's which compete with the 
transport of 6-deoxy-D-glucose. Figures 3.23, 3.24 and 
3.25 illustrates plots from which K-^'s were determined. 
These Kj/s were calculated to be : 5.9 ± 1 .0 mM for 
D-glucose, 32.0 ± 19.4mM for D-mannose and 51.5 ± 3.2 mM 
for D-galactose. D-fructose failed to inhibit 
6-deoxy-D-glucose uptake with any measurable . It can 
be inferred from these results that D-glucose 
(the natural substrate) has the highest affinity
Figure 3.21: A Time course for the uptake of 1OOpM 6- 
deoxy-D-glucose versus time at 20°C, in the RINm5f cell 
line.
11 /2 = *10 ± 0.7 seconds
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Figure 3.22: A Hanes plot of 6-deoxy-D-glucose uptake 
using a 15 second single time point assay at 20°C, in the 
RINm5f cell line.
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Figure 3.23: Inhibition of 1 OOpM 6-deoxy-D-glucose uptake
by D-glucose, in the RINm5f cell line.
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Figure 3.24: Inhibition of 100pM 6-deoxy-D-glucose uptake 
by D-mannose, in the RINm5f cell line.
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for the transporter binding site, followed by D-mannose 
and D-galactose. D-fructose has no ability to inhibit 
sugar uptake at its concentration range.
Inhibition by carbon-1 analogues
There were no analogues available to study the positional 
hydrogen bonding at carbon-1.
Inhibition by carbon-2 analogues 
The analogues used here were 2-deoxy-D-glucose 
and 2-deoxy-D-galactose as inhibitors of 
6-deoxy-D-glucose uptake. The Ki values obtained were
22.9 ± 4.4mM for 2-deoxy-D-glucose and 36.0 ± 0.8 mM for
2-deoxy-D-galactose from figures 3.26 and 3.27. The 
carbon-2 epimer D-mannose inhibited with a
Ki of 32.0 ± 19.4 mM (figure 3.24).
Inhibition by carbon-3 analogues
The 3 position on the hexose ring was studied using
3-0-methyl-D-glucose. It was inferred that
3-0-methyl-D-glucose demonstrates a moderate affinity of 
binding to the transporter with a Ki = 9.5 ± 3.6 mM 
(figure 3.28) .
Figure 3.25: Inhibition of lOO^M 6-deoxy-D-glucose uptake
by D-galactose, in the RINm5f cell line.
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Figure 3.26: Inhibition of 1 OOjjlM 6-deoxy-D-glucose uptake 
by 2-deoxy-D-glucose, in the RINm5f cell line.









Figure 3.27: Inhibition of IOOjjlM 6-deoxy-D-glucose uptake
by 2-deoxy-D-galactose, in the RINm5f cell line.









Figure 3.28: Inhibition of IO O jjlM 6-deoxy-D-glucose uptake 
by 3-0-methylglucose, in the RINm5f cell line.
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Inhibition by carbon-4 analogues
As deoxy analogues were not available, analysis was 
restricted to the 4,6-0-ethylidene-D-glucose analogue.
The Ki value obtained for 4,6-0-ethylidene-D-glucose was
2.4 ± 0.6 mM (figure 3.29). This analogue has a high 
affinity for binding to the transporter site.
Inhibition by carbon-5 analogues
There were no deoxy or thio glucose derivatives available
to study the five position or the ring oxygen.
Inhibition by carbon-6 analogues
The analogues used here were 6-deoxy-D-glucose
and 6-deoxy-D-galactose. 6-deoxy-D-glucose was used as' a
substrate. The Ki for 6-deoxy-D-galactose was
98.4 ± 4.9 mM (figure 3.30). This analogue exhibits a
weak affinity for the transporter binding site.
The fungal inhibitor cytochalasin B binds with 
a K i  = 9.4 ±0.4 jjlM  (figure 3.31). From this it can be 
inferred that cytochalasin B binds to the transporter 
with a moderate affinity. Table 3.2 indicates the 
complete specificity analysis determined by the D-glucose 
analogues available for the study.
Figure 3.29: Inhibition of 1OOpM 6-deoxy-D-glucose uptake
by 4,6-0-ethylidene-D-glucose, in the RINm5f cell line.
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Figure 3.30: Inhibition of 100pM 6-deoxy-D-glucose uptake 
by 6-deoxy-D-galactose, in the RINm5f cell line.
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Figure 3.31: Inhibition of 1 OOpM 6-deoxy-D-glucose uptake
by cytochalasin B, in the RINm5f cell line.









0 4 8 12 16 20
I (uM)
Figure 3.32: Time course for the uptake of 100pM D- 
fructose versus time at 20°C, in the RINm5f cell line, 
ti/2= 24.76 ± 3.60 seconds
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5.9 ± 1.0 
N.D.I.
32.0 ± 19.4 






Fungal inhibitor Cytochalasin B 9.4 ± 0.01 pM
Table 3.2: A table illustrating the results of an 
inhibition study which was performed on the RINm5f cell 
line. A range of D-glucose analogues were used to 
determine their ability to compete with 6-deoxy-D-glucose 
transport. N.D.I. = No Detectable Inhibition.
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3.2.3: D-fructose transport and its inhibition bv 6- 
deoxv-D-alucose
The labelled D-fructose uptake experiments were performed 
using the same assay conditions as for 6-deoxy-D-glucose. 
From figure 3.32, a time course for the uptake of 
D-fructose is plotted. A t-j/2 of 24.76 ± 3.60 seconds was 
calculated. The equilibration of D-fructose was achieved 
in around 2 minutes and maintained for three minutes.
This represents a fairly rapid uptake of the sugar. A 
Hanes plot of D-fructose uptake is plotted in figure 
3.33. Kinetic data was calculated and a Km = 19.50 ±
_-i
2.50mM and Vmax = 2.30 ± 0.36 mMs were determined.
A parallel study with D-fructose inhibition upon the 
uptake of 6-deoxy-D-glucose and vice versa were 
performed. There is no detectable inhibition by 
D-fructose on the uptake of 6-deoxy-D-glucose. The 
results from the converse experiment also indicated no 
detectable inhibition. As both of the sugar labels are 
known to be transported into the RINm5f cell line one can 
infer that there is a difference in the transporter 
specificity, when compared to the HITm2.2 transporter. 
There also may be a heterogeneous transporter population 
present in this cell line with a transporter specific for 
D-fructose.
Figure 3.33: A Hanes plot of D-fructose uptake using a 15 
second single time point assay at 20°C, in the RINm5f 
cell line.
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Figure 3.34: Time course for the uptake of 100jiM 6-deoxy- 
D-glucose versus time at 20°C/ in the HIT-T15 cell line, 
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3.3: Sugar transport into the HIT-T15 cell
3.3.1: 6-deoxv-D-qlucose and D-fructose transport
A limited characterisation with 6-deoxy-D-glucose and 
D-fructose was performed with this cell line. Initially 
these cells were difficult to grow under tissue culture 
conditions. The growth conditions of HIT-T15 cells were 
finally optimised to obtain the quantity of cells which 
were required for transport assays to be performed. There 
was a slight modification in the sugar uptake assay for 
both HIT-T15 and MIN-6 cell. Here the assay was performed 
with the cells attached to the tissue culture dishes. A 
time course for the uptake of 6-deoxy-D-glucose 
is plotted in figure 3.34. From this a t-j/2 of
12.0 ± 0.4 seconds was determined. 6-deoxy-D-glucose was 
equilibrated in around 2 minutes. A Hanes plot of 
6-deoxy-D-glucose transport data is plotted in 
figure 3.35. From this graph the following kinetic data 
were determined. This included a Km = 8.33 ±0.83 mM and a 
Vmax = 0*32 ±0.20 mMs for 6-deoxy-D-glucose. From a 
plot of the fractional filling for D-fructose uptake 
(figure 3.36), a t-| /2 of 23.2 seconds was determined. 
D-fructose reached its equilibrium in 2 minutes. Further 
kinetic analysis revealed a Km of 0.26 ± 0.01 mM with a 
Vmax = 0.37 ± 0.11 mMs-  ^ for D-fructose (figure 3.37).
The intracellular water space accessible to
Figure 3.35: Hanes plot of 6-deoxy-D-glucose uptake using 
a 15 second single time point assay at 20°C, in the HIT- 
T15 cell line.
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Figure 3.36: Time course for the uptake of 100pM D- 
fructose versus time at 20°C, in the HIT-T15 cell line, 
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6-deoxy-D-glucose was determined to be 
0.96pl per 10® cells.
Further experiments looking at the inhibition of 
D-fructose upon the uptake of IOOjiM 6-deoxy-D-glucose and 
vice versa, indicated no detectable inhibition. It is 
likely that these sugars are transported via separate 
transport proteins.
i
3.3.2: D-streptozotocin transport and its inhibition bv 
6-deoxv-D-alucose and D-fructose
The uptake of 100 pM streptozotocin into HIT-T15 cells 
was performed using essentially the same experimental 
transport method as for D-fructose and 6-deoxy-D-glucose. 
Figure 3.38 illustrated a graphical plot depicting the 
uptake of 100pM streptozotocin into the HIT-T15 cell 
line. From this plot the t-| /2 was calculated 
to be 57.8 seconds. D-streptozotocin was equilibrated in 
3 to 4 minutes.
A series of inhibition studies were performed on the 
uptake of streptozotocin in this cell line. D-fructose 
and 6-deoxy-D-glucose were used as substrate's for these 
inhibition studies. Figure 3.39, illustrates a graphical 
plot of 6-deoxy-D-glucose inhibition of streptozotocin 
transport into HIT-T15 cells. A of 28.4 mM was 
calculated. There is no detectable inhibition of
Figure 3.37: Hanes plot of D-fructose uptake using a 1 
second single time point assay at 20°C in the HIT-T15 
cell line.
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Figure 3.38: A time course for the uptake of 1OOpM 
streptozotocin versus time at 20°C in the HIT-T15 cell 
line.








Figure 3.39: The inhibition of 1OOyM streptozotocin 
uptake by the 6-deoxy-D-glucose analogue in the HIT-T15 
cell line.
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Figure 3.40: Time course for the uptake of 100pM 6-deoxy- 
D-glucose versus time at 20°C in the MIN-6 cell line, 
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streptozotocin transport by D-fructose in the HIT-T15 
cell line.
3.4: Sugar transport into MIN-6 cells
3.4.1: 6-deoxv-D-qlucose and D-fructose transport
An analysis of 6-deoxy-D-glucose and D-fructose transport 
were performed with MIN-6 cells. A time course of 
6-deoxy-D-glucose transport is plotted in figure 3.40. 
From this graph, a t ^/2 of 21.6 ± 3.5 seconds was 
determined and this sugar was equilibrated in around 
3 minutes. Experimental results from a Hanes plot 
revealed the following kinetic values for 
6-deoxy-D-glucose transport. A Km = 4.24± 0.44 mM and a
i
Vmax = 0.13 ± 0.03 mMs were determined (figure 3.41).
From figure 3.42 which illustrates plot defining a time
course for D-fructose transport, a t-| /2 of
35.0 ± 1.8 seconds was calculated. D—fructose attained
its equilibrium in around 3 minutes. Parameters of a
kinetic analysis defining D-fructose transport were
calculated from figure 3.43. From this plot a
Km = 7.33 ± 0.47 mM and a Vmax = 0.017 ± 0.009 mMs-  ^ were
determined. A calculation of the intracellular water
space accessible to 6-deoxy-D-glucose in this cell line
was carried out. From this calculation a value of
o
0.63 y.1 per 10 cells was determined.
Figure 3.41: Hanes plot of 6-deoxy-D-glucose uptake using 
a 15 second time point assay at 20°C in the MIN-6 cell 
line.
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Figure 3.42: Time course for the uptake of 1OOpM fructose 
versus time at 20°C in the MIN-6 cell line, 










From figure 3.44 in the MIN-6 cell line, D-fructose 
is reported to inhibit the uptake of 100pM 
6-deoxy-D-glucose. A = 60.5 mM was calculated. 
Conversely the for the inhibition of 100 jiM D-fructose 
(figure 3.45) uptake by the 6-deoxy-D-glucose was 
calculated to be 23.5 mM. From this it can be deduced 
that 6-deoxy-D-glucose and D-fructose are transported by 
the same transporter.
3.4.2: D-streptozotocin transport and its inhibition bv 
6-deoxv-D-qlucose and D-fructose
The plot of the fractional filling defining the uptake of 
1 OOjjlM streptozotocin into the MIN-6 cell line is 
illustrated in figure 3.46. From this figure an 
equilibrium is attained in 3 minutes. A t 1/2 for 
streptozotocin of 30.8 seconds was also determined. In 
the MIN-6 line, 6-deoxy-D-glucose inhibits streptozotocin 
uptake with a Ki = 14.0 mM (figure 3.47). From 
figure 3.47 6-deoxy-D-glucose inhibits transport with a 
greater affinity than in HIT-T15 cells (figure 3.39). 
Figure 3.48 demonstrates a plot for the inhibition 
of D-fructose on the transport of 100pM streptozotocin. 
The sugar analogue inhibits with a calculated 
Ki of 33.3 mM.
Figure 3.43: A Hanes plot of D-fructose uptake using a 15 
second single time point assay at 20°C in the MIN-6 cell 
line.









Figure 3.44: The inhibition of 100pM 6-deoxy-D-glucose 
uptake by the D-fructose analogue in the MIN-6 cell line. 










Figure 3.45: The inhibition of 1OO^M D-fructose uptake by
the 6-deoxy-D-glucose analogue in the MIN-6 cell line.










Figure 3.46: A time course for the uptake of 100pM 
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3.5: An investigation of streptozotocin binding to the 
ervthrocvte transporter
It has been established that there are a number of 
multiple binding sites for cytochalasin B on the 
erythrocyte transporter. The use of cytochalasin E has 
enabled cytochalasin B (a classical fungal inhibitor of 
sugar transport), in the presence of cytochalasin E, to 
bind specifically to a single high affinity site on the 
erythrocyte transporter (Baldwin et a l .. 1982). 
Cytochalasin E is included to bind to the non-specific 
sites which would otherwise be occupied by the ligand of 
interest cytochalasin B.
To be able to study both the binding and the 
transport of the diabetogenic drug streptozotocin, it was 
decided to use erythrocyte membranes as these were 
readily available. In addition the erythrocyte 
transporter is also a well defined system to use as a 
preliminary model. Such membranes were used to look at 
the interaction of the drug with binding sites on the 
membranes. It was anticipated that streptozotocin would 
compete strongly with cytochalasin B for a mutual binding 
site. The analysis took the form of some simple kinetic 
treatment. This treatment included the inhibition of 
cytochalasin B by streptozotocin being studied by two 
approaches. Such a study would enable the precise
104
interaction of the drug to be determined in a well 
defined model system.
3.5.1: Cytochalasin B binding in the presence of 
streptozotocin
This assay was performed with a suitable range of 
streptozotocin concentrations (0 to 20 m M ) . The 
inhibition of the binding of radiolabelled cytochalasin B 
was then studied. In the following study, both the 
inhibitor and the substrate were added to the membrane 
preparation simultaneously to minimise any streptozotocin 
degradation that may occur in solution. Figure 3.49 
illustrates a plot which defines the inhibition by 
streptozotocin on the binding of cytochalasin B to the 
membrane.
Results from this experiment were then subjected to a 
modified Scatchard treatment upon the assumption that 
cytochalasin B will bind to a single high affinity site. 
The Scatchard equation can be written in the following 
form shown below:
[B] = [B m a x ] . [F]
Kd + [F]
Figure 3.49 : A plot illustrating the inhibition of 
cytochalasin B binding to the erythrocyte membrane. The 
inhibitor is streptozotocin. Free/ bound cytochalasin B 
is plotted against the concentration of streptozotocin. 
The inhibition constant (K-^) for streptozotocin is 
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From this equation [B] is the concentration of the bound 
ligand, [F] is the free ligand concentration, Kd is the 
dissociation constant and [Bmax] represents the number of 
identical and non-interacting sites available for ligand 
binding. In the presence of a potential inhibitor such as 
streptozotocin and at low ligand concentrations the 
equation takes the form:
[F] Kd 1 +[i]
[B] tBmax] K i
Thus by plotting the free/ bound cytochalasin B against 
the streptozotocin concentration, the can be 
calculated from the intercept on the x axis. Such a plot 
is displayed in figure 3.49. From this experiment 
the K± for streptozotocin was calculated 
to be 1.89 mM.
A second investigation into the binding of the 
cytochalasin B ligand at two concentrations of 
streptozotocin was performed. A was thus calculated 
from the results of an experiment where the cytochalasin 
B concentration was varied over a defined range. Again 
the results were subjected to a standard Scatchard 
analysis. A plot of the bound/ free against the bound 
cytochalasin B in the presence and the absence of 1OmM 
Streptozotocin is shown in figure 3.50. The appropriate
Figure 3.50: A graphical plot to define the inhibition by 
streptozotocin upon the binding of cytochalasin B to the 
erythrocyte membrane. Cytochalasin B binding in the 
presence of 10 mM streptozotocin (black triangles) is 
compared to cytochalasin B binding on its own (black 








0.4 0.6 0.8 1.00.20.0
Bound Cytochalasin B/mg protein (10~8 mM)
106
kinetic values were determined using the equation of a 
straight line. A B max was calculated from the intercept 
on the x axis, while the binding constant (Kp) was 
obtained from 1/ gradient.
The kinetic values calculated for the binding of 
cytochalasin B in the absence of streptozotocin were a 
Bm ax =0-80 nmol/ mg protein and a Kd = 0.18 pM. In the 
presence of 1OmM streptozotocin the Bmax changed to 
0.78 nmol/ mg of protein, with an apparent Kp (K^i =0.27 
pM) . The inclusion of streptozotocin with cytochalasin B 
resulted in an increase in the for cytochalasin B
without affecting Bm a x . This represents the kinetics of a 
competitive inhibitor, as defined by the following rate 
equation below:
B0 = Bmax-
Kd (1+ [I]/ Ki)+ So
so the Ki [I]
(KDi/ Kd ) -1
From this experiment the streptozotocin is proposed to be 
a competitive inhibitor with a = 21 mM. An overall
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inhibition constant for the binding of streptozotocin is 
calculated to be 11.4± 9.5 mM.
3.5.2: An investigation to determine whether 
streptozotocin binding is reversible or irreversible
An experiment was performed to determine whether 
streptozotocin binds to the erythrocyte membrane 
reversibly or irreversibly. Streptozotocin was initially 
preincubated at a fixed concentration for a range of 
incubation times. The streptozotocin which remained 
unbound to the membrane was removed by a prewash step 
prior to the cytochalasin B binding assay being 
performed. As streptozotocin was not included in the - 
subsequent assay then any inhibition which takes place is 
proposed to be due entirely to that streptozotocin which 
has bound during the initial preincubation step. The 
final fixed concentration of streptozotocin which was 
used for this inhibition study was 10mM. This 
concentration represents approximately half of the 
observed value for streptozotocin (11.4 mM).
A student t test was performed on results from two 
separate experimental populations. The result of the test 
would make it possible to establish whether the Null 
hypothesis could be rejected, that is irreversible 
binding of streptozotocin was statistically significant 
under the defined limits of the t test. The result of the
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Student t test is stated. From statistical tables for the 
student t- distribution, for values exceeded in a two 
tailed test with a probability P. The t values for 
6 degrees of freedom for both of the 5% and 10% levels of 
significance were 2.45 and 3.71. At the 10% level of 
significance there was no significant difference between 
any of the calculated t values and the literature values. 
At the 5% significance level, both of the one hour values 
were significantly different (t-| = 2.77 and t2 = 3.79).
The Null hypothesis is still applicable and irreversible 
inhibition doesn't occur. This is because calculated 
t values for the range of streptozotocin incubation times 
were not significantly different to the literature 
t values. Over a long time period the preincubation of 
streptozotocin doesn't significantly inhibit the binding 
of cytochalasin B. The t test supports the Null 
hypothesis and reversible binding as there is no 
justification from the t values to reject the Null 
hypothesis.
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3.6: The effect of streptozotocin upon sugar transport 
and cell viability
3.6.1: 2-deoxv-D-qlucose transport into HITm2.2 cells 
exposed to streptozotocin
A toxicity study with streptozotocin was performed upon 
the uptake of 2-deoxy-D-glucose into HIT cells. 
Streptozotocin at a 5 mM final concentration was included 
in the tissue culture medium of HIT cells, which were 
incubated for 48 hours. In this assay the HITm2.2 cell 
line was attached to the surface of the tissue culture 
dish. It can be inferred from the results of figure 3.51, 
that 5mM streptozotocin inhibited sugar uptake during 
48 hours. Longer periods of incubation 
(greater than 48 hours) with higher concentrations of 
streptozotocin, resulted in the death and subsequent 
detachment of the cells (results not shown). This made 
the measurement of sugar uptake inconsistent at such time 
periods. Thus for the following 6-deoxy-D-glucose assays, 
concentrations of 20 mM STZ and time periods of 18 hours 
were not exceeded for obvious toxicity reasons.
An experiment was performed to obtain a for the 
inhibition of streptozotocin upon 2-deoxy-D-glucose 
transport. A range of streptozotocin concentrations from 
0 to 40mM were used to study any inhibition. 
Streptozotocin was prepared in solution prior to the
Figure 3.51: A bar graph depicting the results for an 
experiment performed analysing uptake of 2-deoxy-D- 
glucose in HITm2.2 cells. HITm2.2 cells were incubated 
with 5 mM streptozotocin for a time period fo 48 hours. 
The closed bars represent 2-deoxy-D-glucose transport in 
the presence of streptozotocin. The open bars represent 
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start of the experiment in order to minimise any 
degradation which may occur in solution. From figure 3.52 
a K-[ for streptozotocin was calculated in HIT cells. This 
value was 27.5 ± 1.5 mM for the inhibition 
of 2-deoxy-D-glucose.
3.6.2: 6-deoxv-D-qlucose transport into HITm2.2 cells 
exposed to streptozotocin
All experiments here were performed with HITm2.2 cells of 
passage numbers 10 to 15. It has been determined that 
streptozotocin at certain doses targets the beta cell of 
the islet of Langerhans. This destruction of the beta 
cell renders the animal diabetic
(Gunnarason et a l .. 1974). Streptozotocin toxicity can be 
prevented by the inclusion of certain D-glucose 
analogues, which attenuates the toxic effect 
(Kawada et a l ., 1986). The binding of cytochalasin B to a 
high affinity site on the erythrocyte membrane, can be 
prevented by certain concentrations of streptozotocin. To 
investigate whether the specificity of the transporter 
binding site can be correlated to streptozotocin 
toxicity, investigations with streptozotocin were 
performed on cell lines and combined with the data on 
radiolabelled STZ uptake into these lines. To determine 
the effect of streptozotocin, at various concentrations 
and time lengths upon 6-deoxy-D-glucose uptake, the
Figure 3.52: The inhibition of 100y.M 2-deoxy-D-glucose in 
HITm2.2 cells by streptozotocin. A Ki for the inhibition 
by streptozotocin (27.5 ± 1.5 mM) was determined from a 
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following experiments were performed. All of the 
following graphs and tables are a representative example 
of two or more experiments. This is because of the 
variation of the 6-deoxy-D-glucose CPM'S obtained with 
different cell passage numbers on different days. It is 
difficult to account for this CPM variation between 
different assays on a day to day basis.
For these experiments the models of the beta cell 
transporter were the HITm2.2 and RINm5f cells. These were 
seeded and cultured in small scale tissue culture petri 
dishes for approximately 74 hours. During this time 
period both of the cell lines were exposed to various 
concentrations and timed incubations of streptozotocin.
The uptake of the sugar label was performed in 
suspension. First the medium was removed and the cells 
were washed before they were detached and aliquoted in 
preparation for a transport assay. The relevant 
background zero time controls were performed, with all of 
the experiments being carried out in triplicate. Results 
were expressed as the pico moles of 6-deoxy-D-glucose 
transported per milligram of protein. These values were 
plotted against the concentration of streptozotocin or 
the time length of the drug exposure. In each case the 
magnitude of the toxicity is assumed to be proportional 
to the decrease in the 6-deoxy-D-glucose transported by 
the cell line. The activity was calculated from the 
following relationship:
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Activity = (X . ys / z^) / a
X is a constant of 250 pmoles of 6-deoxy-D-glucose, from 
a 50 p.M stock concentration of the label. Ys are the 
CPM'S obtained from the sample. are the total CPM'S 
obtained from a 5ul sample of radiolabelled 
6-deoxy-D-glucose and a is the protein content expressed 
in milligrams. Protein concentration was calculated by 
using the Lowry assay (Lowry et a l .. 1951).
The assays with HITm2.2 cells exposed to various 
concentrations and time lengths of streptozotocin are 
illustrated in a bar chart format. From the data obtained 
in figure 3.53, HITm2.2 cells were preincubated for 
18 hours with streptozotocin at the following four 
concentrations of 0, 5, 10 and 20mM. The cells were 
assayed in triplicate for 6-deoxy-D-glucose transport at 
10 and 600 seconds. A 6-deoxy-D-glucose zero time control 
was performed for all the following experiments. This 
value was subtracted from the final results. It is 
observed from figure 3.53, as the streptozotocin 
concentration increases from 0 to 20mM there is a 
decrease in 6-deoxy-D-glucose uptake. This decrease is 
from 1300 pmol per mg at OmM (600 seconds) to around 
800 pmol per mg at 20 mM streptozotocin. Over the 
10 second time period there is an initial greater 
activity decrease between 0 and 5mM streptozotocin. Here
Figure 3.53: A bar chart illustrating the effect of an 18 
hour incubation of streptozotocin on 6-deoxy-D-glucose 
transport in HITm2.2 cells. Streptozotocin was incubated 
at a range of final concentrations (0,5,10 and 20mM). The 
transport of 6-deoxy-D-glucose (pmol per mg cell protein) 
after 10 seconds (open bars) and 600 seconds (closed 
bars) is plotted against the final concentration of 
streptozotocin. The activity in terms of sugar transport 
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6-deoxy-D-glucose uptake falls from 520 pmol/ mg at 
0 mM to around 167 pmol/ mg at 20 mM streptozotocin.
Figure 3.54 illustrates values for HITm2.2 cells 
preincubated with 10 mM streptozotocin from 0.5 to 
18 hours. From the results shown in figure 3.54, 
6-deoxy-D-glucose transport is reduced as the 
streptozotocin incubation time is increased from 
0.5 to 18 hours. This sugar transport reduction is most 
pronounced from 2 to 6 hours. Between these times there 
is a 100 pmol reduction in the transport activity of 
6-deoxy-D-glucose. This reduction is correlated with an 
increased toxicity.
Figure 3.55 shows an experiment in which HIT cells
were preincubated for 18 hours with 0 and 20 mM
streptozotocin. The 6-deoxy-D-glucose transport activity 
was assayed from 0 to 5 minutes. It can be inferred from
these results that there is a small reduction in
6-deoxy-D-glucose transport into HIT cells, in the 
presence of 20 mM streptozotocin. This reduction in 
transport is compared with cells incubated with 0 mM 
streptozotocin (control).
Table 3.3 shows data on the effects in HIT cells of 
selected incubation of D-glucose,
4,6-0-ethylidene-D-glucose and streptozotocin (5 m M ) . 
These three compounds were incubated for 2, 6 and 
12 hours, in conditions illustrated in table 3.3. This 
table expresses the results of the percentage of dead
Figure 3.54: A graph illustrating the results of the 
effect of streptozotocin upon the transport of 6-deoxy-D- 
glucose in HITm2.2 cells. Streptozotocin is included in 
the culture medium at a final concentration of 10 mM for 
a range of incubation times. These incubation times are 
for 0.5 hours (black circles; solid line), 2 hours (black 
square; dashed line), 6 hours (black triangle; dashed 
line) and 18 hours (black star; dotted line). The 6- 
deoxy-D-glucose transport (activity) is expressed as the 
pmol transported per mg of cell protein and is measured 
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Figure 3.55: A plot showing results which define the 
effect of the long term incubation of streptozotocin upon 
6-deoxy-D-glucose transport in HIT cells. HITm2.2 cells 
were incubated for 18 hours without streptozotocin (black 
circle; solid line) and 20mM streptozotocin (black 
squares; dashed line). The transport of 6-deoxy-D-glucose 
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Table 3.3: A table illustrating the results obtained for 
HITm2.2 cells incubated with + /- glucose, + /- 4,6-0- 
ethylidene-D-glucose (EG) and +/- streptozotocin (STZ) 
for 2, 6 and 12 hours. All the compounds were added to 
the culture medium at a final concentration of 5 mM. The 
results are expressed as the percentage of the dead cells 
observed after the various times. The percentage of dead 
cells was calculated by using a standard cell staining 
technique. Experimental error is shown as the standard 















+ Glucose 0 % 0 % 0 %
- Glucose 34.0 ± 1.0% 63.0 ± 10.0% 97.0 ± 4.5%
+ STZ
+ Glucose 4.0 ± 0.1% 26.0 ± 1.4% 28.0 ± 1.4%
+ STZ




1 0 . 0 ± 0 .2% 30.0 ± 1.4% 65.0 ± 3.2%
114
cells which were calculated from Trypan Blue viability 
tests. In these tests normal cells were compared and used 
as a 100 % viable standard. HIT cells were incubated with 
streptozotocin in the absence of D-glucose for 2, 6 and 
12 hours. After the incubation the number of dead cells 
were determined to be 34, 63 and 97 % dead cells for 
2, 6 and 12 hours. When D-glucose was included in the HIT 
cell medium, the percentage of dead cells was reduced to 
4, 26 and 28 %. The inclusion of
4,6-0-ethylidene-D-glucose with HIT cells resulted in 
1.5, 18 and 97% dead cells being calculated for 2, 6 and 
12 hours. HIT cells were also grown without D-glucose. 
Here the number of dead cells were 10, 30 and 65% over 
2, 6 and 12 hours.
HIT cells were preincubated both with and without 
D-glucose and streptozotocin in the growth medium for 
a 2 hour time period. From the results in table 3.4,
HIT cells were incubated with D-glucose and were compared 
with cells incubated with both D-glucose and 
streptozotocin. It can be inferred from these results 
that HIT cells grown under the two conditions, 
transported 6-deoxy-D-glucose at a similar magnitude for 
both times. This transport activity was at approximately 
400 pmol/ mg and 800 pmol/ mg for 10 and 600 seconds.
HIT cells were also incubated with streptozotocin without 
D-glucose. It could be deduced from this experiment that
Table 3.4: A table showing the effect of HITm2.2 cells 
grown in the presence of + /- glucose and +/- 
streptozotocin (STZ) at final concentrations of 5 mM. 
These incubations were performed for a time period of 2 
hours. The 6-deoxy-D-glucose transport activity was 
measured over 0, 10 and 600 seconds.
Incubation Time Activity
Conditions (seconds) (pmol per mg)
+ Glucose 0 13.0 ± 0.9
- STZ 10 345.0 ± 17.2
600 743.2 ± 30.0
+ Glucose 10 321.1 ± 13.0
+ STZ 600 826.0 ± 5 . 8
- Glucose 10 254.1 ± 8.0
+ STZ 600 500.0 ± 15.0
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6-deoxy-D-glucose transport was reduced to 254 pmol/ mg 
and 500 pmol/ mg over 10 and 600 seconds.
3.6.3: 6-deoxv-D-qlucose transport into RINm5f cells 
exposed to streptozotocin
All these experiments were performed on RIN cells with 
passage numbers from 10 to 15. RINm5f cells were 
preincubated with 0, 5, 10 and 20 mM streptozotocin, 
included in the culture medium for an 18 hour time 
period. It was determined from results displayed in 
figure 3.56 that RIN cells incubated with the 0, 5 and 
10mM streptozotocin, demonstrated a similar sugar 
transport activity. This transport was 100 to 
400 pmol/ mg over 10 and 600 seconds. RIN cells were also 
incubated with 20mM streptozotocin. From figure 3.56, a 
reduction was observed in the sugar transport activity to 
20 pmol/ mg over 10 seconds and 150 pmol/ mg over 
600 seconds. A zero sugar uptake control was calculated 
and this value was subtracted from all the experimental 
values.
RINm5f cells were preincubated with 10 mM 
streptozotocin for 0.5, 2, 6 and 18 hours. In figure 3.57 
the results were calculated and displayed. There was an 
observed decrease in sugar transport from 0.5 to 
18 hours.
Figure 3.56: A graph illustrating results of the effect 
of streptozotocin on RINm5f cells. The streptozotocin was 
incubated for 18 hours at 0, 5, 10 and 20 mM final 
concentrations. 6-deoxy-D-glucose transport was measured 
o v e r .10 seconds (open bars) and 600 seconds (closed 
bars), with a 0 second control being calculated and 
subtracted from all the values. 6-deoxy-D-glucose 
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Figure 3.57: A graph illustrating experimental results of 
the effect of streptozotocin on 6-deoxy-D-glucose 
transport in RINm5f cells. Streptozotocin was included in 
the growth medium at a 10 mM final concentration for a 
range of incubation times. These incubation times were 
0.5 hours (black circles; solid line), 2 hours (black 
squares; dashed line), 6 hours (black triangle; dashed 
line) and 18 hours (black stars; dotted line). 6-deoxy-D- 











0 60 120 180 240 300
Time (seconds)
116
In an experiment, RIN cells were grown for 18 hours 
in 15mM streptozotocin. A simultaneous control experiment 
was performed where cells were grown for the same time in 
the absence of streptozotocin. From figure 3.58, it can 
be concluded from these results that streptozotocin has 
very little effect on 6-deoxy-D-glucose transport. There 
is a small reduction in sugar transport in the absence of 
streptozotocin. This reduction in the control experiment 
may be due to experimental error.
Figure 3.58: A graph showing results which define the 
effect of long term incubation of streptozotocin upon 6- 
deoxy-D-glucose transport into RINm5f cells. RIN cells 
were incubated for 18 hours with OmM streptozotocin 
(black circles; solid line) and 15 mM streptozotocin 
(black squares; dashed line). 6-deoxy-D-glucose transport 
is plotted as an activity (pmol per mg cell protein) 
















The identification of a novel islet type glucose 
transporter Glut 2 (Thorens et a l .. 1988) together with 
the publication of its genetic sequence, has intensified 
research into evaluating the precise role of this unique 
membrane protein. Various aspects of Glut 2 function, 
including its expression, genetic control and a potential 
site of binding for autoantibodies, are being 
investigated. Studies are being undertaken to determine 
what functional role this protein has in glucose 
transport and recognition in insulin secretion and in 
pancreatic disease states.
The binding and subsequent transport of glucose 
across the beta cell membrane is an important step for 
both the production of metabolic energy and glucose 
induced insulin secretion. A full kinetic 
characterisation of this process using a nonmetabolized 
glucose analogue to investigate the hydrogen bonding 
specificity has not previously been performed. There is a 
requirement to perform a thorough investigation of the 
glucose transport protein in islets and islet cell lines 
with a nonmetabolized glucose analogue. One of the aims 
of the work described in this thesis has been to develop 
a suitable transport protocol. Nonmetabolized 
6-deoxy-D-glucose, has been used to study the kinetics of 
transport in isolation from any metabolic effects.
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D-fructose was also used in this investigation as it has 
been reported to be specific for Glut 2 
(Gould et a l ., 1991). Previous studies on glucose 
transport into free islets and beta cell lines are 
sparse. Many studies have used the metabolized analogue
2-deoxy-D-glucose and 3-0-methyl-D-glucose. With
2-deoxy-D-glucose kinetic studies were complicated by the 
phosphorylation of this sugar once it is inside the cell. 
Early studies (not shown in this thesis) have 
demonstrated that 6-deoxy-D-glucose was an effective 
inhibitor of 2-deoxy-D-glucose transport. Since 
6-deoxy-D-glucose cannot be metabolized it was considered 
an important D-glucose analogue for the study of glucose 
transport. An additional aim, was to synthesize and study 
the toxicity, transport and transport inhibitory 
characteristics of the diabetogenic drug streptozotocin.
A radiolabelled analogue was made as this was not 
available commercially. The binding of nonradiolabelled 
STZ to the glut 1 transporter was also studied. The 
glut 1 transporter from erythrocyte membranes is a well 
characterised protein. STZ binding to the erythrocyte 
membrane was determined by studying its inhibitory effect 
on the binding of radiolabelled cytochalasin B. 
Cytochalasin B is known to bind to erythrocytes with a 
high affinity (Lin and Spudich, 1974). The transport of 
radiolabelled streptozotocin was also demonstrated in 
HIT—T15 and MIN-6 cells. Here the transport of STZ and
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the inhibition of this transport with 6-deoxy-D-glucose 
and D-fructose was evaluated. A limited amount of 
information was known about how streptozotocin enters 
cells and it was not known if STZ is transported via the 
glucose transporter. Evidence is presented in this thesis 
that streptozotocin may be transported via the glucose 
transporter of certain beta cell lines. Finally a 
toxicity study was performed in HITm2.2 and RINm5f cells. 
From this study the streptozotocin cytotoxicity was 
correlated with the available hydrogen bonding 
specificity information, pertaining to the hexose ring 
and transporter binding site. Cell viability in terms of 
STZ toxicity was correlated with the 6-deoxy-D-glucose 
transport.
4.1: Synthesis of radiolabelled streptozotocin
Initially Triphosgene was used to synthesize 
N-methylisocyanate (MIC). Triphosgene was reacted with 
radiolabelled glucosamine which resulted in the 
production of radiolabelled streptozotocin. Radiolabelled 
streptozotocin was commercially unavailable and a 
customised synthesis was also inappropriate. It became 
apparent that radiolabelled STZ had to be synthesized 
from glucosamine and MIC. Numerous enquiries to chemical 
companies regarding the purchase of MIC for the 
synthesis, also proved to be unsuccessful. Synthesis of
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MIC had been discontinued partly due to its instability 
during transport and a long shipment time from the United 
States. It was also apparent that the production of MIC 
as well as being highly toxic, was also no longer 
commercially viable. The only alternative to this was to 
perform a synthesis of MIC which would enable STZ to be 
synthesized from glucosamine. The synthesis of MIC was 
performed using two protocols.
The first synthetic method was from triphosgene, 
which is a substitute for the phosgene reagent. Phosgene 
has been used for synthetic chemistry, but it is 
considered unfavourable due to its highly toxic side 
product phosgene gas. This gas is difficult to handle 
safely in the laboratory. Triphosgene 
(Aldrich, Milwaukee, Wisconsin, USA.) is a stable 
crystalline solid (melting point 81- 83°C) which is safer 
and more convenient in terms of transport and storage.
A mechanism for the formation of MIC is described 
here. The nucleophilic methylamine will attack the 
carbonyl carbon of the triphosgene. For the formation of 
MIC to be energetically favourable, phosgene gas and the 
chloride anion are established leaving groups. These 
groups would facilitate the formation of MIC. Under the 
appropriate conditions the equilibrium would favour MIC 
formation, which in theory is then available to react 
with a free glucosamine molecule. Various modifications 
of this method were performed. A variety of solvent
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systems were investigated for both the methylamine and 
triphosgene. The reaction was also performed in the 
presence of glucosamine free base. Here the hypothesis 
was that any MIC which was formed would react immediately 
with the available free glucosamine. Chapter 2 outlines 
in greater detail the various changes made to this 
method, however overall limited success was achieved. The 
final yield of radiolabelled streptozotocin was less than 
10% and it was considered inappropriate to pursue any 
further investigations into the optimisation of this 
protocol. Upon reflection if the MIC synthesis had been 
scaled up and the stoichiometry of the triphosgene 
increased, this may have produced more of the desired end 
product. The limited resources in terms of time and the 
expense of the reagents made this impractical. This first 
method using triphosgene to synthesize MIC was abandoned 
and a suitable alternative method of production of MIC 
was pursued.
The second method which proved to be the more 
successful of the two, involved the in situ distillation 
of MIC. Here the final yield was 40% and any further 
protocol modifications were considered inappropriate. A 
better yield may have been obtained by the use of freshly 
prepared dichlorodiphenylsilane. This compound was shown 
to be unstable, as it decomposed at room temperature upon 
the exposure to light. Freshly distilled quinoline may 
have increased the MIC yield. This distillation of
quinoline had to be performed at a reduced pressure 
(113°C at 17mm Hg) and as quinoline was purchased at the 
highest purity, this distillation was considered 
inappropriate.
Finally freshly distilled MIC was then reacted with 
the glucosamine free base to produce the radiolabelled 
end product streptozotocin. Overall the radiolabelled 
synthesis was successful upon following the distillation 
protocol.
4.2: The kinetics of 6-deoxv-D-qlucose transport
4.2.1: The HITm2.2 transporter and its specificity
The transport of 6-deoxy-D-glucose in HITm2.2 cells was 
found to be rapid at 37°C and it was necessary to reduce 
the temperature to 22°C. HITm2.2 cells were investigated 
for their transporter specificity with 6-deoxy-D-glucose 
and D-fructose. To date there is no available literature 
data to make a direct comparison with these studies.
Early sugar uptake studies into HIT cells were 
performed with 3-0-methyl-D-glucose and
2-deoxy-D-glucose. 3-0-methyl-D-glucose was transported 
with a t 1 /2 f°r equilibration of 21.7 seconds, with 
attainment of equilibrium within 2 minutes. This 
contrasted with 2-deoxy-D-glucose transport. Here the 
sugar never attained isotope equilibrium even after
123
10 minutes. 3-0-methyl-D-glucose transport data obtained 
for HIT cells in this thesis is comparable to similar 
data in islets (Lernmark et a l .. 1975), but contrasts to 
data reported in other cells lines
(Meglasson et a l ., 1986). A t 1/2 of 18 seconds at 37 °C 
for equilibration of 3-0-methyl-D—glucose was reported in 
islets. This contrasted to sugar transport reported in 
other HIT cells (Meglasson et a l ., 1986). Here a 
t 1/2 for 3-0-methyl-D-glucose equilibration of 1 minute 
was reported and full sugar equilibration was reached in 
20 minutes. The transport system expressed in HITm2.2 
cells in this thesis demonstrated a high capacity for 
sugar uptake. This capacity was higher than that obtained 
in islets and other HIT cells. Transport in HIT cells-in 
this thesis was also inhibited by the classical common 
sugar transport inhibitors cytochalasin B and phloretin. 
Therefore the transport system expressed in these cells 
retained recognisable transport characteristics.
The HITm2.2 cells in this thesis equilibrated 
6-deoxy-D-glucose in 60 seconds (t 1/2 of 17.3 s), which 
was similar to 3-0-methyl-D-glucose equilibration. 
Meglasson (et a l ., 1986) reported that
3-0-methyl-D-glucose transport in HIT-T15 cells, reached 
equilibrium after 20 minutes. This is contrary to 
6-deoxy-D-glucose transport in HITm2.2 cells. 
6-deoxy-D-glucose transport rates are similar to those in 
dispersed islets (Lernmark et a l ., 1975). In these islets
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3-0-methyl-D-glucose was equilibrated in 60 seconds 
i/2= 10 seconds). Here HITm2.2 cells in this thesis 
demonstrated rapid transport of 3-0-methyl-D-glucose and 
6-deoxy-D-glucose across the membrane. The transporter 
possess certain glut 2 characteristics.
The transport system in HITm2.2 cells possessed a 
K± of 1.65 pM for the cytochalasin B inhibition of 
6-deoxy-D-glucose transport. This can be compared to a 
value of 1.9 pM for the inhibition of
3-0-methyl-D-glucose in hepatocytes which contain glut 2 
(Axelrod and Pilch, 1983). In islets cytochalasin B 
inhibited 3-0-methyl-D-glucose transport with a Kj_ = 1 pM 
(Johnson et a l .. 1990b).
The Km for 6-deoxy-D-glucose transport in HITm2.2 
cells was 2.07 mM with a Vmax of 0.21 mM s . These 
kinetic values were not similar to 3-0-methyl-D-glucose 
studies with islets. In islets the reported Km is 17mM 
(Johnson et a l .. 1990b). Vmax values for hepatocyte
_ -|
3-0-methyl-D-glucose transport, varied from 1.3 mM s 
(Craik and Elliott, 1979) to 0.005 mM s- ^
(Goresky and Nadeau, 1974). A HITm2.2 Vmax of 0.33 mM s-  ^
(Chen et a l ., 1990) for 3-0-methyl-D-glucose transport 
has also been determined.
Hexose transport specificity in HITm2.2 cells was 
studied with a range of inhibitors of 6-deoxy-D-glucose 
transport. The hydrogen bonding requirements were 
investigated with deoxy analogues of D-glucose. Spatial
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constraints to binding were investigated with various 
hexoses, substituted with bulky groups at the appropriate 
positions.
Specificity at Carbon-2 (C-2)
Inhibition of 6-deoxy-D-glucose transport by D-mannose 
(C-2 epimer), 2-deoxy-D-glucose and D-galactose indicates 
that negligible hydrogen bonding occurs at C-2. 
Erythrocyte and adipocyte transporters 
(Barnett et a l .. 1973; Holman et a l .. 1981) show a 
similar C-2 hydrogen bonding specificity. In the 
intestinal sodium cotransport system (Crane, 1960) there 
is an absolute requirement for the gluco-configuration at 
C-2.
Specificity at Carbon-3 (C-3)
The Ki for 3-0-methyl-D-glucose inhibition of 
6-deoxy-D-glucose transport was calculated to be 10 mM. 
From this kinetic value it can be concluded that 
3-0-methyl-D-glucose bound with a moderate affinity to 
the transporter. The methyl group may contribute to some 
spatial interference at this position. The oxygen may 
partake in some hydrogen bonding with the transporter 
protein. This could explain the moderate affinity of this 
glucose analogue for the transporter binding site. 
3-0-methyl-D-glucose is rapidly transported by 
erythrocytes, adipocyte and islet cells and is non-
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metabolised (Whitesell and Gliemann, 1979). There have 
been some reports of the slow transport of 
3-0-methyl-D-glucose by certain cultured cell lines 
(Meglasson et a l ., 1986).
Specificity at Carbon-4 (C-4)
Deoxy glucose analogues were unavailable and it can be 
inferred that moderate inhibition of 6-deoxy-D-glucose 
uptake by D-galactose (K^= 21 mM) indicated that a 
glucose configuration is non-essential for binding to the 
HITm2.2 glucose transport protein. This transporter 
appears to demonstrate a fairly broad specificity.
Partial inhibition by 4,6-0-ethylidene-D-glucose 
(Ki= 100 mM), probably due to steric interference by the 
ethylidene group indicates a close approach to the 
binding site by C-4. There is both spatial freedom and 
limited hydrogen bonding at the C-4 position in most 
mammalian transport systems.
Specificity at Carbon-6 (C-6)
The C-6 hydroxyl group is not required for any hydrogen 
bonding as the Km for 6-deoxy-D-glucose indicated that 
the transporter has the same affinity as that for D- 
glucose. Hydrophobic bonding may occur at this position 
as 6-deoxy-D-galactose appears to demonstrate zero 
affinity for the transporter.
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D-Fructose is transported rapidly by HITm2.2 cells 
with a t-| /2 f°r equilibration of 12 seconds. The Km for 
D-fructose is 2.58 mM. From this value it can be deduced 
that D-fructose has a high affinity for the transporter
_ i
binding site. The V max for D-fructose is 0.047 mM s , 
which is lower than that determined for 6-deoxy-D-glucose 
(Vmax= 0.31 mM s- 1 ) in HITm2.2 cells. A comparison with 
literature data obtained with HIT—T15 cells was made.
Here a weak D-fructose competition with D-glucose uptake 
was reported (Ashcroft and Stubbs, 1987). D-Fructose is 
transported by Glut 2 but not by Glut 1 or 3. Human 
Glut 2 expressed in Xenopus Oocytes transported 
D-fructose at a rate of 0.8 pmol/ min/ oocyte 
(Gould et a l ., 1991). D-fructose also inhibited
2-deoxy-D-glucose transport in these cells.
Inhibition studies on D-fructose transport were 
performed in these cells. It was concluded that 
D-fructose only partially inhibited the uptake of 
6-deoxy-D-glucose, with a K± = 228.0 mM. Conversely 
6-deoxy-D-glucose inhibited D-fructose transport 
(Ki = 52.0 mM) in HITm2.2 cells. From these results, it 
can be concluded that both D-fructose and 
6-deoxy-D-glucose may bind with different affinities to 
the same sugar transport system in HITm2.2 cells. It 
would appear that the transport system in this cell line 
retains similar characteristics to Glut 2 and has certain 
differences to other reported cell lines. There may be a
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separate transporter for D-fructose in these cells which 
also shows affinity for 6-deoxy-D-glucose.
4.2.2: The specificity of hexose transport in the RINm5f 
cell line
The sugar transport inhibitor phloretin at 100 uM final 
concentration, was observed to reduce both 
3-0-methyl-D-glucose and 2-deoxy-D-glucose transport in 
RIN cells. From these studies the RINm5f cell line 
appears to posses a phloretin sensitive transporter.
6-deoxy-D-glucose is transported rapidly with an 
equilibrium being reached in 50 seconds
1/2 f°r equilifc>ration= 10 s). The 3-0-methyl-D-glucose 
kinetics of the RINm5f transporter were previously only 
briefly investigated (Trautmann and Wollheim, 1987). From 
this work, the transporter was reported to possess a high 
capacity and a low affinity for D-glucose. In these cells 
3-0-methyl-D-glucose was equilibrated at 37 °C within 
2 minutes (Trautmann and Wollheim, 1987). In the RINm5f 
transporter, D-glucose (K± =5.9 mM) has a high affinity 
for the transporter binding site and is able to compete 
strongly with 6-deoxy-D-glucose transport. D-mannose 
(Ki= 32 mM) and D-galactose (K^= 52 mM) are also able to 
compete with 6-deoxy-D-glucose for transport. In the 
RINm5f cell, D-fructose was not able to inhibit 
6-deoxy-D-glucose transport. This transporter appears to
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be specific for D-glucose (K-l = 5.9 mM) as the latter 
bound with a similar affinity to 6-deoxy-D-glucose 
(Km = 3.62 m M ) . In comparison to the RINm cells, the 
HIT m2.2 transporter demonstrates greater affinity for 
both D-glucose (Ki for 6-deoxy-D-glucose transport= 2 mM) 
and 6-deoxy-D-glucose (Km = 2.07 m M ) . D-fructose cannot 
be shown to inhibit 6-deoxy-D-glucose binding in RINm5f 
cells. This contrasted with HIT m2.2 cells where only a 
small inhibition of D-fructose on 6-deoxy-D-glucose is 
observed. In the RIN m5f cell line, D-mannose inhibits 6- 
deoxy-D-glucose transport with a K-[ of 32 mM, which is 
less than D-glucose but more than D-galactose. In the 
HITm2.2 cell line D-mannose bound with a stronger 
affinity to the transporter (Ki of 9 mM) when compared to 
the RIN m5f line (K^= 32mM). D-Galactose is the weakest 
of the three sugars (Ki = 52 mM), while in the HIT m2.2 
cells the latter bound with a higher affinity of 21 mM.
Specificity at carbon-2 (C-2)
Moderate inhibition of the carbon-2 epimer D-mannose 
(Ki = 32 mM), 2-deoxy-D-glucose (Ki = 23 mM) and
2-deoxy-D-galactose (Ki = 36 mM) upon 6-deoxy-D-glucose 
transport indicate that the 2 position may be involved in 
some hydrogen bonding with the transporter. It is 
apparent that there is limited space between the sugar 
and the hydroxyl group, at the C-2 position. This 
reduction in space is due to the interaction through
hydrogen bonding, bringing the sugar into closer contact 
with the protein.
Specificity at carbon-3 (C-3)
The carbon 3 position was analysed using 
3-0-methyl-D-glucose. This bound to the protein with a 
moderate affinity (K^ = 9.5 m M ) . The specific binding of
3-0-methyl-D-glucose and its ability to compete with 
6-deoxy-D-glucose for a mutual binding site, indicated 
that the 3 hydroxyl group does not participate in a 
hydrogen bond at this position. The tolerance of the 
methyl group at the 3 carbon position leads to the 
proposal of a degree of spatial freedom at this position. 
There may be space between the transporter and the sugar 
at this position.
Specificity at carbon-4 (C-4)
A limited analysis was performed at the Carbon 4 
position. This was due to the unavailability of both the 
fluoro and deoxy analogues at this position. The C-4 
epimer D-galactose (Ki = 52 mM), displayed a moderate 
inhibition of 6-deoxy-D-glucose transport and bound with 
a fairly low affinity. 4,6-0-ethylidene-D-glucose bound 
with a high affinity to the transporter (Ki = 2.36) 
comparable with D-glucose. It was concluded from this 
affinity that there was a degree of spatial freedom 
around the 4 and 6 positions. Without information from
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the deoxy and deoxyfluoro analogues no conclusions as to 
the hydrogen bonding requirements could be made.
Specificity at Carbon-6 (C—6)
The effectiveness of 6-deoxy-D-glucose as a substrate 
(Km = 3.62 mM) and the observation of 6-deoxy-D-galactose 
binding with a low affinity indicated that the 6 hydroxyl 
group may participate in some hydrogen bonding. D-glucose 
and D-galactose which contain the 6 hydroxyl group were 
observed to bind to the RIN transporter. As expected 
D-glucose bound with a high affinity (K^ = 5.9 mM), 
whereas D-galactose bound with only a moderate affinity 
(Ki = 52.0 mM). This confirms the possibility of hydrogen 
bonding at this position.
The RIN m5f cell line has a for cytochalasin B of 
10 pM. This is similar to the hepatic, islet and HIT m2.2 
cells where the = 2 uM. Cytochalasin B binds with a 
low affinity to the RINm5f transporter, which may 
indicate a possible structural difference at the 
cytochalasin B binding site. Here 6-deoxy-D-glucose has a 
Km of 3.62 mM and a Vmax of 0.43 mM s . This is not 
comparable to islets where a Km = 17mM and a vmax= 0.53
_-i
mM s were reported (Johnson et a l ., 1990b).
D-Fructose is transported fairly rapidly (t -j /2 for
_ 1
equilibration of 20 seconds; vmax= 2.30 mM s ) and is 
equilibrated in around 3 minutes. The Km for D-fructose 
in RIN cells is 19.5 mM. From these results, the
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transporter has a moderately high affinity, high capacity 
transport system with respect to D-fructose (Km = 2.58mM 
in HITm2.2 cells). It has been reported that hepatocyte 
cells may posses a separate D-fructose transporter 
(Okuno and Gliemann, 1986). In RINm cells, D-Fructose 
exhibits no detectable inhibition of 6-deoxy-D -glucose 
transport or vice versa. As both sugars are reported to 
be transported, one can infer that there may be a 
heterogeneous transporter population in RINm5f cells. In 
terms of the fast equilibration of the 6-deoxy-D-glucose 
sugar across the membrane, the RIN cell transporter 
exhibited certain Glut 2 characteristics. It is 
reasonable to propose that these cells may express a 
transporter with certain unique properties which requires 
further confirmation and investigation.
4.2.3: The sugar transport kinetics of the HIT-T15 cell 
line
Studies performed with 6-deoxy-D-glucose and D-Fructose, 
provided some kinetic details of the transport system 
present in this cell line. The 6-deoxy-D-glucose analogue 
was transported with a t *j /2 for equilibration of 
11 seconds and it reached equilibrium in 2 minutes. The 
intracellular water space accessible to 6-deoxy-D-glucose 
was calculated to be 0.92 )jl1 / 10® cells. This value was 
compared to a similar value for 3-0-methyl-D-glucose
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transport of 0.62 p.1/ 10® cells (Meglasson et a l . , 1986). 
Meglasson (et a l ., 1986) also observed that
3-0-methyl-D-glucose was only equilibrated after 
20 minutes. In the work in this thesis the transport of 
6-deoxy-D-glucose compared favourably with the uptake of
3-0-methyl-D-glucose into dispersed islet cells 
(Lernmark et a l ., 1975). In islets, 3-0-methyl-D-glucose 
equilibration was achieved in 1 minute with a t -| /2 for 
equilibration of 15 seconds. In the HIT-T15 cell the 
Km for 6-deoxy-D-glucose is 8.33mM. This value was 
compared with that obtained from islets and liver cells 
(Johnson et a l ., . 1990b). In these cells the Km was 
between 17 and 20 mM. HIT-T15 cells also displayed a 
vmax °f 0.32 mM s-  ^ for 6-deoxy-D-glucose, which can be 
compared to islets where a vmax was obtained for
3-0-methyl-D-glucose (0.53 mM s- ^ ). These HIT-T15 kinetic 
values were determined at low passage numbers 
(10 and 15). Certain cell lines were reported to express 
an erythrocyte type transporter at higher cell passage 
numbers (above 60). One such line is the RIN cells and 
certain hepatocyte cell lines (Thorens et a l ., 1988). 
There are conflicting reports that other cell lines 
express a transporter with an islet specificity 
(Miyazaki et a l ., 1990; Purrello et a l .. 1991). The 
HIT—T15 line possessed here appears to demonstrate an 
islet type specificity, which is reflected in the kinetic
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parameters for 6-deoxy-D-glucose and D-fructose 
( Km/ high capacity).
There is no literature data available to compare 
D-fructose transport kinetics with the data on D-fructose 
transport in the HIT-T15 cell line obtained here. 
D-fructose is transported rapidly (t 1/2= 23.2 seconds) 
and equilibrated in 2 minutes. The Km for D-fructose was 
calculated to be 0.26 mM. It was concluded from this that 
the sugar has a strong affinity for the transporter 
binding site. The Vmax for D-fructose was 0.37 mM s . 
This value supports a transport system with a fairly high 
capacity for this sugar. A series of experiments looking 
at the inhibition of D-fructose upon the uptake of 
6-deoxy-D-glucose and vice versa were performed. The 
results of these experiments were inconclusive and no 
inhibition was demonstrated by either sugar upon one 
another. Thus it would appear that both sugars are not 
transported by one and the same transporter. The liver 
cell is reported to possess a separate fructose 
transporter (Okuno and Gliemann, 1986), so the presence 
of a heterogeneous transporter population in this cell 
line cannot be ruled out. D-fructose is transported by 
human Glut 2 but not by Glut 1 or 3 (Gould et a l .. 1991).
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4.2.4: The sugar transport kinetics of the MIN-6 cell 
line
The MIN-6 line is reported to contain a high level of 
Glut 2 mRNA (Miyazaki et al 1990), with low levels of 
Glut 1. MIN-6 cells were acquired fairly recently from 
Dr. Miyazaki and a preliminary kinetic characterisation 
was performed with 6-deoxy-D-glucose and D-fructose. This 
investigation provided specificity information on the 
type of transporter expressed in these cells. The 
intracellular water space in MIN-6 cells accessible to
o
6-deoxy-D-glucose was calculated at 0.63 pi per 10 
cells. This can be compared to a value for
o
3-0-methyl-D-glucose (0.62 pi per 10 cells) reported by 
Meglasson (et a l ., 1986). From initial results with 
6-deoxy-D-glucose studies, it was determined that MIN-6 
cells possessed a high capacity transporter 
(t-|/2 for equilibration= 21.7 seconds), which 
equilibrated 6-deoxy-D-glucose in 2 minutes. Again sugar 
transport appears not to be rate limiting and can be 
compared to 3-0-methyl-D-glucose uptake into islets 
(Lernmark et a l ., 1975) and liver cells 
(Williams, 1968). The MIN-6 Km for
6-deoxy-D-glucose was calculated at 4.24 mM, with a vmax 
of 0.13 mM s“ 1 . Such values could again only be compared 
with values for 3-0-methyl-D-glucose obtained from islets 
(Km = 12 to 30 mM; vmax of 0.53 mM s~^)
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(Johnson et a l ., 1990b). These MIN-6 cell kinetic 
parameters were determined using cells at a low passage 
number. Conclusions drawn from the kinetic data 
contrasted the hypothesis that certain beta cell lines 
expressed Glut 1 exclusively. From the preliminary 
kinetic data and the finding of Glut 2 mRNA being present 
(Miyazaki et a l ., 1990), the MIN-6 cell line appears to 
fit the model of the pancreatic beta cell line (Km is 
lower than that expected for Glut 2)
(Thorens et a l ., 1988). Here MIN-6 cells possess a high 
capacity high affinity type (Glut 2) islet transporter. 
This hypothesis was determined from results of 
experiments which used nonmetabolized 6-deoxy-D-glucose 
as the substrate.
It was also demonstrated in MIN-6 cells, that 
D-fructose was equilibrated (t-| /2= 35.0 seconds) in 
around 3 minutes. A Km and a vmax for D-fructose were 
calculated at 7.33 mM and 0.02 mM s . The inhibition 
studies performed on MIN-6 cells produced conclusive 
results. D-fructose was demonstrated to inhibit 
6-deoxy-D-glucose transport (K^= 60.5 mM) and 
6-deoxy-D-glucose also inhibited D-fructose uptake 
(K^= 23.5 m M ) . Thus it can be concluded that both of 
these sugars are transported or bind to one and the same 
transporter. The kinetics of this transporter are similar 
to Glut 2. Work for the future would be to perform a full
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kinetic characterisation of the hydrogen bonding 
specificity in this cell line.
The synthesis of a limited quantity of radiolabelled 
streptozotocin enabled a brief study of its uptake. The 
inhibition of the transport of 6-deoxy-D-glucose and 
D-fructose by streptozotocin was also studied. The 
HIT—T15 and MIN-6 cell lines were chosen to study the 
anticipated transport of the radiolabelled drug. From 
these results streptozotocin appeared to be transported 
by MIN-6 and HIT-T15 cells. The latter equilibrates STZ 
in under 4 minutes (t 1/2= 57.8 seconds), whereas MIN-6 
cells attained an equilibrium after 3 minutes 
(t 1/2= 31.0 seconds). Preliminary inhibition studies 
indicated that transport in HIT-T15 cells was inhibited 
by 6-deoxy-D-glucose (K^ = 28.4 mM), with no detectable 
inhibition being able to be shown with D-fructose. The 
MIN-6 cell line was different and 6-deoxy-D-glucose 
inhibited STZ transport (K^ = 1 4  mM) along with 
D-fructose (Ki = 33.3 m M ) . It would appear that there are 
specificity differences between the binding site in both 
of these cell lines, in terms of both the uptake of 
streptozotocin and the analogue that can inhibit this 
uptake. Work for the future would be to obtain a Km for 
streptozotocin in these and the other cell lines. 
Inhibition studies could also be performed with a variety 
of other sugar analogues and the fungal inhibitor 
cytochalasin B, to determine more specificity information
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on the binding of this drug and prove unequivocally that 
it is transported by a specific transporter.
4.3: The effect of streptozotocin upon cytochalasin B 
binding to ervthrocvtes
Prior to the availability of cell lines and as isolated 
islets were not easy to obtain in sufficient quantities, 
the affinity of streptozotocin for the cytochalasin B 
binding site was studied in erythrocytes.
There was some evidence to indicate that STZ was 
transported via the glucose carrier in both erythrocytes 
and islets (Kawada et a l .. 1987). These authors have 
demonstrated that 4,6-0-ethylidene-D-glucose prevented 
streptozotocin accumulation in rat pancreatic tissue. 
Transport of streptozotocin has been reported to vary in 
certain cell types. Pancreatic and liver cells have been 
shown to possess the highest recorded uptake rates of STZ 
(Anderson et a l ., 1974).
From studies in this thesis, it can be inferred that 
streptozotocin inhibited the binding of cytochalasin B to 
the erythrocyte (K^= 1.89 mM). As there was no available 
literature data to compare with these studies, it was 
inferred that the streptozotocin bound at or near to the 
cytochalasin B binding site on Glut 1. From the structure 
of streptozotocin one can propose that the drug can 
interact with the glucose carrier via the
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2-deoxy-D-glucose moiety. This association is believed to 
occur through specific hydrogen bonds with the 
transporter binding site. It was also predicted that 
streptozotocin would bind reversibly to the transport 
protein. This was demonstrated by a student t test which 
defined the long term binding of STZ, in the presence of 
radiolabelled cytochalasin B. The results of the test 
supported the Null hypothesis and that no irreversible 
binding of STZ to the transporter statistically occurred. 
If streptozotocin is transported via the glucose carrier 
then irreversible binding would restrict transport at the 
vital sites upon the protein.
From a Scatchard plot it was concluded that STZ 
competitively inhibited cytochalasin B binding 
(K±= 21 mM). Cytochalasin B has previously been 
demonstrated by other authors to competitively inhibit 
the erythrocyte carrier with a of between 0.26 and 
0.4 pM (Jung and Rampal, 1977). The presence of 1OmM 
streptozotocin caused an increase in the respective 
Kd (0.27 pM from 0.18 pM at 0 mM streptozotocin), without 
affecting the Bm a x . This is the recognisable kinetics of 
a competitive inhibitor and provides further evidence for 
specific reversible binding of streptozotocin.
From these initial results cytochalasin B 
(the substrate) and streptozotocin (the inhibitor) were 
unable to bind simultaneously to the transporter site as 
they were in competition for that same site or at least a
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site within close proximity. It is well documented that 
cytochalasin B can competitively and stochiometrically be 
displaced by glucose and other substrate's at the glucose 
transporter site (Jung and Rampal, 1977). Streptozotocin 
can competitively displace cytochalasin B from binding to 
glut 1 and this is evidence that the former will bind to 
the glucose transporter or the cytochalasin B site close 
to or at the transporter. The overall for the binding 
of streptozotocin was 11.4 ± 9.4 mM. Conformation of this 
was provided by the uptake of radiolabelled 
streptozotocin into HIT-T15 and MIN-6 beta cells which 
has not been previously been demonstrated.
4.4: Streptozotocin and its effect upon cell viability 
and the transport of D-glucose analogues into the HITm2.2 
and RINm5f cells.
Experiments were performed with 2-deoxy-D-glucose and 
streptozotocin which was included to study its effect on 
2-deoxy-D-glucose transport. HITm2.2 cells were cultured 
for 48 hours in the presence of 5 mM streptozotocin. It 
was concluded from these results that STZ produced an 
approximate 50 % reduction in 2-deoxy-D-glucose transport 
(figure 3.51). The K-[ for streptozotocin was calculated 
to be 27.5 mM (figure 3.52). From the it was inferred 
that streptozotocin competitively inhibited 
2-deoxy-D-glucose transport. Streptozotocin appeared to
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be transported by the same transporter as 
2-deoxy-D-glucose, but further conformation showing the 
uptake of radiolabelled streptozotocin was required. 
Radiolabelled streptozotocin was synthesized but only a 
limited amount was available for a kinetic study to be 
performed. Streptozotocin transport was studied in 
HIT—T15 and MIN-6 cell lines.
From work with animal models, the destruction of the 
beta cell by streptozotocin can be prevented by
4,6-0-ethylidene-D-glucose and other sugar analogues 
being included (Kawada et a l .. 1986). There is limited 
evidence for a specific streptozotocin/ glucose 
recognition site being present on the beta cell membrane 
(Kawada et a l .. 1987). It is not clear whether the 
toxicity of streptozotocin is related to its specificity 
of binding to the transporter and what transport system 
is specific for streptozotocin transport. The sugar 
transporter specificity may differ between the HIT, RIN 
and MIN-6 cell lines and some evidence for that 
difference is provided here. Specificity of the sugar 
transporter is also compared and contrasted with glut 2.
From figure 3.53 the results calculated for HITm2.2 
cells exhibited a trend towards a reduction in 
6-deoxy-D-glucose transport. This reduction in sugar 
transport is proportional to an increase in 
streptozotocin concentration over an 18 hour incubation. 
HITm2.2 cells were incubated for times of 0.5 to 18 hours
142
in the presence of 1OmM Streptozotocin (figure 3.54). It 
was concluded from this result that the exposure of cells 
to 50% of the final concentration of STZ, appeared to 
decrease 6-deoxy-D-glucose transport. The greatest 
reduction in sugar transport was between 2 and 6 hours. 
HITm2.2 cells incubated for periods greater than 18 hours 
(results not shown) were non viable. An 18 hour 
incubation of HITm2.2 cells with 15 mM streptozotocin was 
performed. It was concluded from these results that sugar 
uptake was moderately reduced (figure 3.55). There are no 
literature experiments to compare with this HIT cell 
toxicity study. This toxicity data can provide evidence 
that streptozotocin is able to inhibit the transport of 
6-deoxy-D-glucose in HIT cells. These results support the 
hypothesis that streptozotocin competes with D-glucose 
for a mutual binding site upon the membrane. This theory 
is also supported by radiolabelled streptozotocin uptake 
studies.
A viability study was performed on HITm2.2 cells 
which were incubated with streptozotocin, D-glucose and
4.6-0-ethylidene-D-glucose under defined conditions 
(table 3.3). It was concluded from the results that
4.6-0-ethylidene-D-glucose and D-glucose, added to the 
culture medium could prevent the cytotoxic actions of 
streptozotocin. From table 3.3, the number of dead cells 
with D-glucose and 4,6-0-ethylidene-D-glucose were 
reduced over 2, 6 and 12 hours, compared to the cells
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incubated with streptozotocin. Over a 2 hour period there 
was an 8.5 fold protection from cell death due to 
D-glucose and a 23 fold protection as a result of 
4, 6-0-ethylidene-D-glucose being included with 
streptozotocin. A control experiment was performed on HIT 
cells without both D-glucose and streptozotocin. From 
these results it could be inferred that a portion of the 
dead cells was due to the absence of D-glucose in the 
media. The increase in HIT cells death was more 
pronounced at longer time periods of incubation. At 
6 hours, it was inferred from this result that there was 
a 2 and 4 fold protection compared with only 
streptozotocin, by D-glucose, 4,6-0-ethylidene-D-glucose 
and a D-glucose absence. It can also be concluded from 
the results for 12 hours, that there was a 3.5, 0 and 1.4 
fold protection from the death of the cells. This was due 
to the inclusion of D-glucose, 4,6-0-ethylidene-D-glucose 
and zero D-glucose. 4,6-0-ethylidene-D-glucose appeared 
to lose its protective capacity over a longer period of 
time. This suggested that it was displaced from the 
binding site or that cell death resulted from a lack of 
nourishment. A parallel glucose protection experiment 
against STZ was carried out over 2 hours (table 3.4). In 
this experiment 6-deoxy-D-glucose transport was 
correlated with cytotoxicity. From this study it could be 
observed that there was a reduction in 6-deoxy-D-glucose
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transport when streptozotocin was present and D-glucose 
was absent.
It can be concluded from the results obtained in this 
thesis that the HITm2.2 cell line was sensitive to 
streptozotocin. There is also further evidence to propose 
that the D-glucose transporter was the site of uptake for 
the drug. Uptake of radiolabelled streptozotocin into the 
MIN and HIT cell lines provided evidence to support the 
transport of STZ via the 6-deoxy-D-glucose transporter 
specifically, or at a site in close proximity to the 
latter. Kawada (et a l ., 1986) have reported on the 
protection against streptozotocin toxicity in the beta 
cell which occurs with 4,6-0-ethylidene-D-glucose. This 
analogue has been observed to bind exofacially to human 
erythrocytes (Barnett et a l .. 1975) and rat adipocyte 
(Holman and Rees, 1982). From these two literature 
citings, 4,6-0-ethylidene-D-glucose was proposed to be an 
asymmetric non transported inhibitor of D-glucose 
transport. The induction of diabetes with STZ was thought 
to provide some indirect evidence for the participation 
of a specific transport protein in the membrane of both 
cultured and collagenase isolated beta cells. Other 
transported analogues namely 3-0-methyl-D-glucose and
2-deoxy-D-glucose (Gonda et a l .. 1976), are also proposed 
to protect against streptozotocin toxicity in islets. 
Researchers in this scientific field have speculated upon 
the existence of an unknown membrane transporter pool.
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This pool of transporters may possess a unique 
specificity which may be similar to Glut 2. It has been 
proposed that such a transporter will specifically 
recognise the 2-deoxy-D-glucose moiety of streptozotocin.
Evidence for a specific transporter which recognised 
the D-glucose moiety of STZ has been reported by Kawada 
(et a l .. 1986; Kawada et a l ., 1987). This group performed 
some experiments in suitable animal models and islets, 
which produced evidence for the protection by
3-0-methyl-D-glucose against the toxic effect of 
streptozotocin. Kawada (et a l .. 1987) also demonstrated 
that 2-deoxy-D-glucose and N-acetylglucosamine exhibited 
protection against cytotoxicity. The
alpha-O-methylstreptozotocin analogue was demonstrated to 
be nondiabetogenic in beta cells, with neither the 
counterpart sugars alpha-0-methyl-3-0-methyl-D-glucose 
and alpha-0-methyl-2-deoxy-D-glucose being shown to 
prevent cytotoxicity. The beta anomer of Streptozotocin 
was reported to be less diabetogenic than the alpha 
anomer (Rossini et a l ., 1977). D-mannose and D-galactose 
were also demonstrated to be nondiabetogenic when they 
replaced the 2-deoxy-D-glucose moiety on the 
streptozotocin molecule.
The RINm5f cell line was subjected to a similar 
toxicity study. From figure 3.56 RINm5f cells were 
incubated for 18 hours with 0, 5, 10 and 20 mM 
streptozotocin. From these results RIN cells are able to
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tolerate streptozotocin incubation. This tolerance is 
indicated from the result showing a small decrease in 
sugar transport as the streptozotocin concentration is 
increased. There is a reduction in 6-deoxy-D-glucose 
transport in the presence of 20 mM streptozotocin. At 
this concentration the drug may exert other unknown 
nonspecific effects on the cell, not related to sugar 
uptake. This may indirectly effect the sugar transporter 
in these cells. This contrasted to the HITm2.2 cell line 
where the cells appeared to be more sensitive to 
streptozotocin. RINm5f cells when incubated from 0 to 
18 hours with 1OmM streptozotocin, results are 
demonstrated which show again that these cells tolerate 
streptozotocin (figure 3.57). This is correlated with a 
small reduction in 6-deoxy-D-glucose transport. Data for 
the incubation of 15mM streptozotocin for 18 hours 
produced results which show that these cells are able to 
tolerate streptozotocin. Any observed decrease in the 
transport activity was negligible (figure 3.58). There 
were no parallel literature comparisons available for 
RINm cells, as studies had only been performed with 
isolated islets. The few studies performed on RINm5f 
cells demonstrated that these cells exhibited a degree of 
tolerance to another diabetogenic agent alloxan 
(Sener and Malaisse, 1985). These authors have speculated 
that the resistance to toxicity in these cells to this 
agent, is involved with the D-glucose transporter binding
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site. Fairly recently Ledoux and Wilson (1984) studied 
the effect of streptozotocin upon the RIN-r cell line. 
This group concluded that these cells were not as 
sensitive to the drug as were isolated beta cells.
4.5: A correlation of the binding site specificity with 
the toxicity of streptozotocin.
Table 4.1 illustrates the range of s obtained for both 
of the HITm2.2 and RINm5f cells. The differences in 
specificity between these two cell lines with respect to 
the inhibiting sugars upon the uptake of 100 pM 
6-deoxy-D-glucose were as follows. For the natural 
substrate D-glucose, the inhibition constants were the 
same within the limits of experimental error. The 
D-fructose sugar, while no detectable inhibition on 
6-deoxy-D-glucose transport could be observed in RINm5f 
cells, it did appear to inhibit 6-deoxy-D-glucose 
transport in HITm2.2 cells with some specificity. As for 
the other sugars, D-mannose and D-galactose demonstrated 
a slightly greater affinity for the transporter binding 
site in HITm2.2 cells.
At the two and three positions upon the carbon ring, 
the hydrogen bonding between the sugar and the protein is 
proposed to be the same for both cell types. Each cell 
line was able to tolerate a bulky side group at the 
3 position and this analogue bound with a moderate
Table 4.1: A table to compare and contrast the K-j/s of D- 
glucose analogues, on 100pM 6-deoxy-D-glucose transport 
in the HITm2.2 and RINm5f cells. 2DG = 2-deoxy-D-glucose, 
2DGAL = 2-deoxy-D-galactose, 3MG = 3-0-methyl-D-glucose, 
EG = -4,6-0-ethylidene-D-glucose, 6DG = 6-deoxy-D-glucose, 
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affinity to the binding site. There was a difference in 
affinity to the transporter observed with
4,6-0-ethylidene-D-glucose, as the latter bound with a 
stronger affinity to the RINm5f cell line. The 4 and 6 
positions were fairly important to enable hydrogen 
bonding to have taken place in the HITm2.2 transporter. 
This was supported by the weak inhibition of the 6-deoxy- 
D-galactose label in HITm2.2 cells, which further 
supported the existence of hydrogen bonding at the C-6 
position. Figure 4.1 illustrates the model for the 
established specificity of the Glut 1 binding site.
From the specificity information obtained on the HITm2.2 
transporter binding site, this cell line has important 
hydrogen bonding sites with the carbon 2 and 3 positions 
on the hexose ring. The carbon 4 and 6 positions appear 
to be less important hydrogen bonding sites in the HIT 
cell. Specificity data obtained on the RINm5f cell line 
give a different model for D-glucose binding to the 
transporter site. In this cell line, the important 
hydrogen bonding sites are carbons 3, 4 and 6, while 
carbon 2 appears to be not so important for hydrogen 
bonding to take place with the transporter binding site.
Finally the difference between the transporter 
binding site specificity in HIT and RIN cells can be 
correlated to the difference in cytotoxicity between 
these two cell lines. HIT cells exhibit 4 fold more 
affinity for 2-deoxy-D-glucose than RIN cells. This may
Figure 4.1: A model of the D-glucose carrier complex in 
the human erythrocyte (from Barnett et a l . , 1973). The 
broken lines indicate the proposed hydrogen bonding 
interactions between the sugar hexose ring and the 
transporter protein.
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account for HIT cells increased sensitivity to 
streptozotocin as this compound has a 2-deoxy-D-glucose 
moiety in its structure. It is proposed that HIT cells 
bind streptozotocin with a greater affinity, which 
facilitates an increased transport of the drug. This 
increased binding affinity and transport will result in 
an increased cell toxicity in HIT cells. RIN cells only 
display a moderate affinity for 2-deoxy-D-glucose which 
may lead to a poor binding and more tolerance of the 
toxic effects of streptozotocin. As RIN cells were able 
to tolerate the toxic effects of streptozotocin at 
certain concentrations, it was considered inappropriate 
to perform any protection experiments with
4.6-0-ethylidene-D-glucose. RIN cells display up to 50 
fold more affinity for 4,6-0-ethylidene-D-glucose than 
HIT cells. It is speculated that
4.6-0-ethylidene-D-glucose may protect against 
streptozotocin toxicity more than in HIT cells, due to 
the analogues affinity for the RIN cell transporter 
binding site. On the results produced in this thesis, 
there appears to be structural differences between the 
RIN and HIT D-glucose transporter binding sites. These 
specificity differences may account for differences in 
the binding and transport of streptozotocin.
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4.6: Future work
A) The specificity study could be extended to clarify 
the requirements at the 2,3,5 and 6 carbon positions.
This would establish whether the models for the substrate 
carrier complex proposed in this discussion are correct.
B) Further kinetic studies with radiolabelled 
streptozotocin are required to be performed to establish 
the Km and vmax values for the drug. Some further work to 
study the specificity of the hydrogen bonding in the 
MIN-6 and HIT-T15 cell lines is also necessary. These 
studies would use the same 6-deoxy-D-glucose analogues.
C) There is a further requirement to study the 
toxicity of streptozotocin in these beta cell lines, 
correlating the cytotoxicity with the quantity of insulin 
secreted. An enzyme linked immunosorbant assay (ELISA) 
was developed for a more precise determination of the 
insulin secretion as a measure of the toxicity. Further 
studies would be performed with the MIN-6 cell line as it 
constitutes the best model of the beta cell. This is 
based on the kinetic data determined in this thesis, 
together with the reported insulin secretory pattern and 
glut 2 mRNA when compared with collagenase isolated islet 
beta cells. This ELISA would enable the transport of 
D-glucose to be correlated with the secretion of insulin 
in the MIN-6 cell. Cell viability could then be
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established as to whether the transport of D-glucose is 
reduced before insulin secretion.
D) A study of the glucokinase enzyme activity 
together with the transport of D-glucose could also be 
studied with a working assay to determine the activity of 
the enzyme. It has been speculated that both the 
transporter and the glucokinase enzyme may associate to 
ensure the transport and identification of D-glucose, in 
the early part of glucose identification. It has been 
proposed that the function of certain intracellular amino 
acids upon the D-glucose transporter may take part in 
some form of association with the glucokinase protein. 
This may be essential for the initiation of the insulin 
secretory response to occur.
4.7: Conclusions
Glucose transport into the beta cell is the first stage 
in the identification of glucose and the response in 
terms of insulin secretion. To understand the binding 
specificity of the islet type transporter can only assist 
in the aetiology of pancreatic metabolic breakdown, 
namely diabetes. The work here has attempted to 
characterise the hexose transport process, in particular 
with respect to streptozotocin binding to the D-glucose 
transporter and the associated cell toxicity.
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